Predictors of the Health Effects of Marijuana Use on the Hepatic Function by Gbogbo, Makafui Kokou
Walden University 
ScholarWorks 
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral Studies Collection 
2020 
Predictors of the Health Effects of Marijuana Use on the Hepatic 
Function 
Makafui Kokou Gbogbo 
Walden University 
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations 
 Part of the Epidemiology Commons, Public Health Education and Promotion Commons, and the 
Quantitative, Qualitative, Comparative, and Historical Methodologies Commons 
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies 
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an 
authorized administrator of ScholarWorks. For more information, please contact ScholarWorks@waldenu.edu. 
  
 
Walden University 
 
 
 
College of Health Sciences 
 
 
 
 
This is to certify that the doctoral dissertation by 
 
 
Makafui K. Gbogbo 
 
 
has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  
the review committee have been made. 
 
 
Review Committee 
Dr. Manoj Sharma, Committee Chairperson, Public Health Faculty 
Dr. Garland Brinkley, Committee Member, Public Health Faculty 
Dr. Aaron Mendelsohn, University Reviewer, Public Health Faculty 
 
 
 
 
 
Chief Academic Officer and Provost 
Sue Subocz, Ph.D. 
 
 
 
Walden University 
2020 
 
 
 
  
  
 
Abstract 
Predictors of the Health Effects of Marijuana Use on the Hepatic Function 
by 
Makafui K. Gbogbo 
 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Philosophy 
Public Health 
 
 
Walden University 
May 2020 
  
Abstract 
The quantity of marijuana use, the length of time it was used, and the age of initiation of 
the drug are at the core of the discussions about the potential health effects of marijuana 
use on the liver. Results of recent studies regarding how the drug affects human health 
have resulted in a number of conflicting conclusions. Nevertheless, based on these 
findings, marijuana users are being denied liver transplants. The objective of this study 
was to identify predictors of the health effects of marijuana on the liver and provide 
guidance in the care management of marijuana users. To address the inconsistencies in 
the research findings, this study was designed to investigate possible associations 
between the quantity of marijuana use, the duration of use, and the age of initiation as 
they relate changes in liver enzymes. Data from a random sample of 702 participants 
obtained from the National Health and Nutrition Examination Survey were analyzed in a 
least square linear regression model. The study found that the quantity of marijuana use 
has a significant effect on the serum total bilirubin (TB) level with an apparent 
detrimental effect on the serum level of TB, R2 = .106, F(3, 19) = 4.859, p < .05, 95% CI 
[-.896, -.175]. The duration of use significantly affects the serum level of alkaline 
phosphatase, R2 =.074, F(4, 18) = 4.661, p < .05, 95% CI [.00, .004] and total protein, R2 
= .077 F(4, 18) = 3.401, p < .05, 95% CI [-.013, .000]. The age of initiation failed to have 
a significant health effect on any liver enzymes. This study has the potential to improve 
care management for marijuana users by helping to accelerate the diagnosis process and 
by improving the policy of liver transplant denial for marijuana users. 
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Chapter 1: Introduction to the Study 
In 2013, the National Institute of Drug Abuse (NIDA, 2015) reported a significant 
increase in the number of people who were using illicit drugs, which was primarily 
associated with the increase in marijuana use due to the new laws that decriminalized the 
drug (Maier, Mannes, & Koppenhofer, 2017). Drinking alcohol, smoking tobacco, and 
the use of cocaine decreased over the same time period (NIDA, 2015), while the rise in 
marijuana consumption resulted in an increase in cannabis-related emergency department 
visits (Zhu & Wu, 2016). Results of recent studies regarding how the drug affects human 
health have resulted in a number of conflicting conclusions. Some studies found a 
significant therapeutic effect of the drug on human health, including a positive effect on 
the liver, whereas other research warned of marijuana’s adverse health effects (Adejumo 
et al., 2017, Volkow et al., 2014). In the medical field, many questions related to the 
actual impact of the drug on different organs of the human body, the impact of the drug 
on less frequent users, and the effect of the age of initiation and method of consumption 
of the drug remain unanswered (Sznitman & Room, 2018).  
In recent years, more studies related to marijuana use have emerged (Maier, 
Mannes, & Koppenhofer, 2017). Researchers have begun to investigate the risk factors 
associated with marijuana and how it affects different human organs including the liver 
(Gudsoorkar & Perez Jr., 2015; Kazory & Aiyer, 2013). Although many findings are still 
in their early stages, they appear to point in many different directions, including reports 
of positive and negative health effects, as well as no significant health effect (Adejumo et 
al., 2017; T. Liu et al., 2014; Terry-McElrath et al., 2017). It is important to note that 
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several of these studies were conducted on groups of individuals with preexisting liver 
conditions, which has the potential to be a source of bias in the findings. In more than 
half of these studies, researchers did not consider the age of initiation of cannabis use, the 
duration of cannabis use, the quantity of cannabis use, or the method of consumption in 
their analysis (Sznitman & Room, 2018). The few studies conducted with healthy 
participants failed to distinguish marijuana users from those who were using or abusing 
other substances. For instance, several studies reported difficulties in isolating those 
individuals who only use cannabis, which has the potential to reduce the sample size and 
can negatively impact and skew study results (Quraishi, Jain, Chatterjee, & Verma, 
2013). In addition, when evaluating the effect of marijuana on the liver, most studies 
failed to consider the difference in age, gender, and race. These unique sociodemographic 
factors are potentially important and may affect the results of these studies.  
In 2015, more than 11 million Americans reportedly consumed marijuana (NIDA, 
2015). The prevalence of marijuana use more than doubled from 2001-2002 to 2012-
2013, which coincided with an increase in the number of cannabis-related emergency 
department visits and marijuana-related admissions in hospitals and residential service 
treatments (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2014). Interestingly, clear evidence of adverse health effects of marijuana use on the liver 
was inconsistent. Researchers then began questioning why liver transplants were being 
denied to marijuana users and whether marijuana should be classified as a Schedule I 
drug. More studies are essential to fully understanding the actual effects of marijuana on 
the liver.  
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In the laboratory, the health of the liver is assessed by identifying the serum levels 
of liver function parameters such as the serum level of alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), albumin (ALB), alkaline phosphate (ALP), total 
bilirubin (TB), total protein (TP) and the gamma-glutamyl transpeptidase (GGT) 
(Fumeaux, Scarpelli, Tettamanti, & Palmiere, 2018). These parameters are indicative of 
different functions of the liver and help to assess the health condition of the liver. Hence, 
the scope of this study was to analyze how marijuana affects them individually, which is 
valuable in the identification of specific effect of the drug on a healthy liver.  
Accordingly, in this study, I analyzed the predictors of the health effects of 
marijuana on the liver function in different categories of users and evaluated whether the 
age of initiation, the length of time marijuana was used, and the amount of marijuana 
smoked daily have a significant effect on hepatic function. 
Background 
The core issues associated with the health effects of marijuana use on the liver 
have been found to be related to the user’s age, the age of initiation, the amount of 
marijuana smoked, the method of consumption and the preexisting condition of the 
smokers (Sznitman & Room, 2018). 
Age is a risk factor for many chronic diseases including liver diseases (H. Kim et 
al., 2015). Previous research has indicated that younger individuals who use marijuana 
are less at risk of developing nonalcoholic fatty liver disease (NAFLD) than older 
individuals are (D. Kim et al., 2017). The age-specific onset of marijuana use has varied 
throughout history. The percentage of adolescents who tried marijuana before the age of 
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13 years increased between 1991 and 1999, but a steady decrease has been observed from 
1999 to 2015 (Youth Risk Behavior Surveillance System (YRBSS, 2017). For example, 
after using marijuana for more than 30.5 months with an average age of onset of 21.8 
years, 34 patients presented no abnormal liver function tests (Kotan et al.,2017). By 
contrast, at the age of onset of 15.31 years with 9.53 years of smoking marijuana, 51% of 
cannabis dependent patients displayed abnormal liver patterns (Quraishi et al.,2013). 
These findings suggest that the duration and the amount of marijuana were critical factors 
in determining the detrimental health effects of the drug on the liver. The conclusions 
from the above findings were different from other findings that suggested marijuana use 
has a therapeutic effect on NAFLD and the severity of hepatitis C virus (HCV) infection 
(Adejumo et al., 2018; D. Kim et al., 2017). This contradictory conclusion suggested that 
the more marijuana is used and the longer it is used, the more positive effect it has on the 
NAFLD and HCV-infected patients. Terry-McElrath et al. (2017) and Quraishi et al. 
(2013) also found that the duration of marijuana use is a factor that should be taken into 
consideration when analyzing the health effects of marijuana. Terry-McElrath et al. 
(2017) associated increased risk of adverse health effects of 50-year-old marijuana users 
with moderate to heavy long-term use of marijuana. In addition, Quraishi et al. (2013) 
linked the long-term use of marijuana to abnormal liver patterns. The quantity of 
marijuana used has also been considered in several studies that evaluated the impact of 
marijuana on the liver. Adejumo et al. (2017) suggested that heavy cannabis use 
represents a positive contributing factor on the prevalence of NAFLD, whereas Terry-
McElrath et al. (2017) concluded that the intensity of marijuana smoked is a strong 
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predictor of negative health effects for 50-years old users. Unlike previous studies, T. Liu 
et al. (2014) found no significant difference in the health of the liver of 21 patients 
infected with HCV who used marijuana compared to HCV-infected nonusers.  
Several previous studies have assessed the impact of marijuana on specific liver 
enzymes and found conflicting results. Mohamed et al. (2015) concluded that chronic 
marijuana use was associated with the hepatic enzymatic alteration. Several other studies 
have reported results that indicated the detrimental health effect associated with 
marijuana on liver enzymes, including ALT, AST, ALP, TB, ALB, TP, and GGT. 
(Mohamed et al., 2015; Quraishi et al., 2013; Wani, Khan, & Singh, 2017). In contrast to 
the findings of the above authors, some studies have suggested that marijuana improves 
the activity of the liver enzymes (Adejumo et al., 2018; Kim et al., 2017) while another 
research group found no significant health impact of the drug on hepatic function (Kotan 
et al., 2017; Muniyappa et al., 2013; Rahmayanti et al., 2017). 
Problem Statement 
Marijuana is the most common illicit drug used in the U.S. (NIDA, 2015). 
Concerns about its use are reportedly associated with its adverse cognitive effect 
(Mandelbaum & de la Monte, 2017) and its likelihood to cause adverse cardiovascular 
events (Thomas, Kloner, & Rezkalla, 2014). With the recent change in social attitudes 
toward the use of marijuana and its continued decriminalization (Maier et al., 2017), there 
has been an increase in interest related to risk factors associated with use of the drug and 
how it affects several organs in the human body (Gudsoorkar & Perez Jr., 2015; Kazory 
& Aiyer, 2013). Predictors of the health effects of alcohol and tobacco on the liver are 
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well documented (Liu et al., 2017). However, except for a single study published in 
Brazil in 2004 (Borini, Guimarães, & Borini, 2004) that attempted to evaluate the 
predictors and health effects of marijuana use on the liver in a healthy population, studies 
of risk factors associated with the effects of marijuana use on the liver in healthy 
populations are relatively scarce in the literature. For example, when Kim et al. (2017) 
showed that marijuana use is associated with NAFLD and Tarantino, Citro, and Finelli 
(2014) found that marijuana use potentially creates health risk in patients with 
concomitant chronic liver diseases, neither study assessed how the difference in the 
amount of marijuana use, the length of time it was used, and how the age of initiation 
may have differently affected the study results. In addition, these studies did not assess 
the risk factors associated with individual liver function markers, as each of them may be 
indicative of other liver health issues. 
To close the gap in the literature, the intent of this study was to identify potential 
predictors of the health effects of marijuana use on hepatic function while examining the 
association between the number of joints or pipes of marijuana smoked daily, the age of 
initiation, the length of time the drug was used, and the individual liver function markers 
using a large nationally representative sample. 
Purpose of the Study 
The purpose of this study was to identify potential predictors of the liver health 
effects associated with marijuana use on hepatic function, while also examining the 
effects of the number of joints or pipes use daily, the age of initiation, and the length of 
time marijuana was used. In a cross-sectional analysis, this study used the number of 
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joints or pipes smoked daily, the age of initiation, and the duration of use as the 
independent variables, and the biochemistry profile of the liver, including the serum level 
of ALT, AST, ALB, ALP, TB, TP, and GGT were used as the outcome variables. I 
categorized the population sample by the age of the study participants, the age of 
initiation, and the length of time the drug was regularly used. The study approach reduced 
bias or the possible confounding effects of liver risk factors by controlling for aging 
factors, gender, alcohol use and body mass index (BMI). 
Research Question 
The research question addressed in this study was as follows: Is there any 
significant association between the number of joints or pipes of marijuana smoked in a 
day, the age of initiation, the duration of use and each of the serum level of liver function 
markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and GGT while 
controlling for the age of participants, their gender, the average alcohol use and BMI? 
H01: There is no significant association between the number of joints of marijuana 
smoked in a day, the age of initiation, the duration of use and each of the serum level of 
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and 
GGT while controlling for the age of participants, their gender, the average alcohol use 
and BMI. 
H11: There is significant association between the number of joints of marijuana 
smoked in a day, the age of initiation, the duration of use and each of the serum level of 
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and 
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GGT while controlling for the age of participants, their gender, the average alcohol use 
and BMI. 
Theoretical Framework 
This study was grounded in the ecosocial theory introduced by Krieger in 1994 
(Krieger, 2011). The key premise of this theory is that the pattern of health and disease 
can be explained by a complex web of interconnected risk and protective factors rather 
than by direct causative agents (Krieger, 2011). The theory explains how exposure to 
certain commodities, such as tobacco, alcohol, and illicit drugs are possible pathways that 
affect the physiology and gene expression in humans, which, in turn, affects their health 
outcomes (Krieger, 2011).  
The major construct of ecosocial theory, embodiment, entails the claim that 
disease and health pattern are the results of what humans biologically embody during the 
course of their life and that disease can be explained not only by innate factors, but also 
by the effects of exogenous factors on the human body (Krieger, 2011). Alongside the 
core construct, the theory calls for attention to the joint interplay of exposure, 
susceptibility, and resistance at multiple levels across the course of a person’s life 
(Krieger, 2011). Acknowledging the pathway of the joint interplay of exposure, 
susceptibility, and resistance helps to identify exposures, potential confounders, and 
effect modifiers concerning the social group, time, and place (Krieger, 2011). It is also a 
critical pathway for evaluating the likely impact of risk factors on disease burden 
(Krieger, 2011). The theory allows for better conceptualization to examine risk factors 
associated with diseases at the individual and population levels (see Figure 1).  
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Adapting ecosocial theory to this study reveals that understanding the health 
effects of marijuana use on the liver requires the examination of the social and biological 
risk factors that mediate the relationship between marijuana use and hepatic function (see 
Figure 1). The embodiment construct facilitates a better understanding of the major 
factors that are associated with marijuana use. Kalant (2004) reported that the early onset 
of marijuana use, especially weekly or daily use, are strong predictors of future adverse 
health effects, and Borini et al. (2004) found that the health effects of cannabis depend on 
the dose received. The interconnection of these risk factors and their roles in the 
physiology and gene expression in the human body are evidence of adverse health 
outcomes such as liver diseases. Hall (2009) observed that it is challenging to assess risk 
factors associated with adverse health outcomes of cannabis use only because users are 
also likely to use alcohol, tobacco, and other illicit drugs. This observation points to the 
potential presence of confounders and/or effect modifiers concerning risk-factor 
assessment and analysis in marijuana users, which Krieger (2011) proposed to elucidate 
or evaluate using the pathway of the joint interplay of exposure, susceptibility, and 
resistance (see Figure 1).  
This theoretical framework provides the basis to understand the exposures to 
marijuana use and to evaluate associated risk factors and their impact on the hepatic 
function.  
Considering the key premise of ecosocial theory that exposure to certain risk 
factors affects the physiology and gene expression in humans, which are the source of 
many diseases (Krieger, 2011), with the exposure pathway that called attention to the 
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joint interplay of exposure, susceptibility, and resistance, the results of this study are 
expected to provide insight into how the age of initiation, the daily dose of marijuana use, 
and the frequency at which marijuana is used affect liver function of users. 
 
 
Figure 1. Ecosocial theory and embodying inequality: core constructs. (Krieger, 1994; 
Krieger, 2008). Reprinted from Krieger, N. (1994). Ecosocial Theory of Disease 
Distribution. In N. Krieger (Ed), Epidemiology and people’s Health: Theory and Context 
(pp. 202-235). New York, NY: Oxford Press. 
Nature of the Study 
The study had a primarily quantitative cross-sectional design with a focus on 
secondary data collected from the National Health and Nutrition Examination Survey 
(NHANES, National Center for Health Statistics [NCHS], 2015b). Data analysis will take 
into consideration several parameters that assess the risk of developing liver diseases 
when the organ is exposed to marijuana use. The study will consider only sample 
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participants aged 20 to 59 years old. An approach of data analysis will use a complex 
sample general linear model (CSGLM) in SPSS where the outcome variables need to be 
continuous and the predictor variables can be categorical or continuous. The CSGLM 
takes into consideration the multistage sampling method use during the NHANES data 
collection. A deep analysis of the statistical tools and the effects of confounding variables 
will be considered and assessed later during the study. 
Definition of Variables 
In this section, I define the key variables in the context of this project. 
Independent Variables 
Number of joints or pipes smoked daily: In the context of this project, this 
variable is related to the number of joints or pipes of marijuana or hashish, an individual, 
male or female aged 20 to 59 years smoked in a day.  
Age of initiation: This is the age at which an individual, male or female, aged 20 
to 59 years, began regularly using marijuana or hashish. 
Duration of marijuana use: This was the period in a lifetime when marijuana was 
used. 
Dependent Variables 
Alanine aminotransferase (ALT): ALT is a circulating transaminase in human 
serum and a specific marker for liver dysfunction (Huang et al., 2017). According to the 
NHANES data documentation and description, an elevated level of ALT can be 
indicative of hepatic disease, myocardial infarction, and/or muscular dystrophy and organ 
damage. In the context of this study, ALT will be assessed to diagnose liver disease. 
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Aspartate aminotransferase (AST): As a liver enzyme, AST increased during liver 
dysfunction. Apart from being elevated in liver diseases, the activity of the enzyme is 
also influenced by certain disease states, such as myocardial infarction, muscular 
dystrophy, pulmonary emboli and acute pancreatitis (Marshall, Lapsley, Day, & Ayling, 
2014). In the context of this study, AST will be used uniquely for its ability to diagnose 
liver disease.  
Alkaline phosphatase (ALP): Alkaline phosphatase is another enzyme used as part 
of liver function analysis to evaluate possible dysfunction of the liver (Bishop et al., 
2018; Lowe & John, 2018). Because it is a nonspecific enzyme, 80% of ALP found in the 
serum originates from the liver, bones, and in small amounts from the intestine. The 
enzyme serves as a marker of extrahepatic cholestasis such as stones in the bile duct or 
intrahepatic cholestasis such as drug-induced cholestasis or biliary cirrhosis (Bishop et 
al., 2018; Lowe & John, 2018; Sharma, Pal, & Prasad, 2014). The enzyme will be used in 
the context of this study to evaluate liver dysfunction.  
Total protein (TP): Synthesized in the liver, the evaluation of serum total protein 
is useful to assess the synthetic ability of the liver. Although the protein level is not a 
sensitive marker for liver damage, it is useful to quantify the severity of liver dysfunction 
(Bishop et al., 2018). In the context of this study, TP will be used to evaluate liver 
dysfunction. 
Albumin (ALB): Synthesized by the liver, Albumin is the major form of protein in 
human serum, which is involved in maintaining proper osmotic pressure and the transport 
of various substances through the body (Bishop et al., 2018; Morman & Varacallo, 2018). 
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A low concentration of albumin is most commonly associated with possible liver disease 
(Morman & Varacallo, 2018). In the context of this study, the level of serum albumin will 
be employed as a liver disease marker.  
Total bilirubin (TB): Bilirubin is a breakdown of old and damaged red cells 
collected in the liver. Sometimes the body can have an excessive amount of bilirubin, 
which is referred to as hyperbilirubinemia and recognized as jaundice (yellow 
discoloration of the skin, eyes and mucous membranes) when the excess is accumulated 
in the tissue (Bishop et al., 2018). According to the NHANES data documentation and 
description, elevated bilirubin is associated with hemolytic jaundice, internal hemorrhage, 
acute hemolytic anemia, while low bilirubin is associated with chronic nephritis and 
aplastic anemia. In the context of this study, variations in bilirubin levels will be 
exclusively measured to assess the presence of liver-related diseases.  
Gamma-glutamyl transaminase (GGT): Elevated activity of GGT is found in liver 
dysfunction, hepatobiliary disorders and chronic alcohol consumption (Bishop, 2018; 
Koenig & Seneff, 2015). A drug such as warfarin, phenobarbital, and phenytoin are noted 
to increase the enzyme level. According to the NHANES data documentation and 
description, GGT is the most sensitive marker of liver disease. 
Controlled Variables 
Alcohol use: In the context of this study, alcohol consumption is categorized into 
light drinkers (less than 2 drinks per day), moderate drinkers (2 to 4 drinks per day), and 
heavy drinkers (4 or more drinks per day). One drink is defined as a 12-oz beer, a 5-oz 
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glass of wine, or 1.5 oz of liquor (National Institute on Alcohol Abuse and Alcoholism, 
n.d.) 
Body mass index (BMI): In the context of this study, BMI refers to the weight in 
kilograms of any participant divided by his or her height in meters squared, rounded to 
one decimal place.  
Age: In the context of this study, age refers to the age of the participants at the 
date of screening. 
Gender: In this study, the gender of the participants can be male or female. 
Definition of Terms 
Marijuana: Also known as weed, herb, pot, grass, bud, ganja, and “Mary Jane,” 
marijuana refers to the dried leaves, flowers, stems, and seeds from the hemp plant, 
Cannabis sativa. Marijuana used in a hand-rolled cigarette is referred to as a joint, and it 
is referred to as a pipe when used in pipes or in water pipes.  
Delta-9-tetrahydrocannabinol (THC) is the main psychoactive chemical, 
responsible for the intoxicating effect found in marijuana. It is mainly found in the resin 
produced by the leaves and buds of the cannabis plant.  
Hepatitis is an inflammation of the liver. There are many types of hepatitis 
depending on etiological factors. Viral hepatitis is caused by a viral infection, and 
depending on the type of virus, viral hepatitis can be subdivided into hepatitis A through 
E. Alcoholic hepatitis, caused by increased alcohol consumption is also common. Other 
medical conditions such as autoimmune diseases can also cause inflammation of the liver 
Snyder, 2016). 
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Assumptions 
Although the different markers employed in this study are known in the diagnosis 
and treatment of other diseases, they were exclusively used in this study for their function 
in liver-related diseases.  
The age of initiation or the age of onset usually refers to the age at which an 
individual had the first contact with marijuana or hashish. But in the context of this study, 
the age of initiation or the age of onset was assumed to be the age at which an individual 
had contact with marijuana or hashish and continued using it for at least one year. 
Scope and Delimitations 
This study was limited to participants aged 20-59 years old, ages at which 
marijuana use may not have a considerable effect on the liver. Younger or older members 
of the population may display a different pattern of the effect of marijuana on the liver. 
This study was also unable to account for the difference in the size of joints or pipes of 
marijuana and the variation in the daily amount used. Furthermore, this study does not 
consider any gender difference when assessing the data. Although the gender-related 
health effect of marijuana on the liver could be mentioned during analysis, it is not the 
fundamental objective of this study.  
Participants who tested positive for hepatitis B and C were excluded from the 
study because such individuals may develop an increased level of liver enzymes that 
could interfere with the study results. It has been proven that these patients develop an 
increased level of ALT and AST (Bishop et al., 2018). Other liver diseases, such as 
NAFLD, liver cirrhosis and liver cancer also commonly increase the level of liver 
16 
 
enzymes (Bishop et al., 2018). Unfortunately, data on these diseases which could have 
improved the relationship between the different variables were not available to introduce 
them in the current study for analysis.  
In brief, this study could not establish a cause-effect relationship, but it was 
designed to be capable of identifying associations between possible predictors and 
outcome variables (Asomoah, 2014). 
Limitations 
In any research study, it is important to acknowledge the limitations. These 
limitations should focus on the problems related to the research question(s) being studied 
(Connelly, 2013). The NHANES data have an important number of missing marijuana 
use data due to the sensitivity of the drug use questionnaires. For this study, I ignored any 
case with one or more missing data points, which evidently reduced the sample size. To 
avoid possible selection bias caused by such procedure, I considered and combined data 
collected over several years (2009 to 2016). To make the data representative of the 
general population and as recommended by the NHANES, I adjusted the dataset for the 
weight to indicate the combination of four years of data collection cycles.  
It is important to note that the NHANES data were self-reported answers to a 
series of questions. Although subjected to many processes of verification to ensure 
accuracy, self-reported data are always prone to bias (Connelly, 2013). 
Significance of the Study 
An increase in the number of people consuming illicit drugs was reported in 2013 
by the NIDA (2015). The increasing decriminalization of marijuana was identified as a 
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major contributing factor to the rise of the drug consumption (Maier et al., 2017). More 
than 11 million Americans used marijuana in 2015 alone (NIDA, 2015). While alcohol 
drinking, tobacco smoking, and cocaine use have decreased over the years (NIDA, 2015), 
marijuana use is on the rise, which has resulted in more cannabis-related emergency 
department visits (Ayangbayi et al., 2016). Not only was research on the health effects of 
marijuana on the liver scarce in the literature, but the findings in the studies that were 
available were also conflicting. Although some findings suggested a therapeutic effect of 
the drug on the liver (Adejumo et al., 2017; Kim et al., 2017), other findings warned of its 
adverse effects on human health (Wolkow et al., 2014). Researchers also lack approaches 
to assess possible predictors such as the age of initiation, the quantity of marijuana use, 
and the duration for which it was used in the analysis of the health effects of marijuana 
on hepatic function.  
By analyzing the impact of the age of initiation, the quantity of marijuana use, and 
the duration for which marijuana was used on the individual liver enzymes, this study 
was intended to provide insight on the predictors of the health effects of marijuana on the 
liver. Liver enzymes were assessed individually because each of them indicates a 
different health status of the liver. 
Summary 
In Chapter 1, I presented the scope of the study, including the nature and the 
different assumptions of the study. In Chapter 2, the literature review, the state of 
marijuana use in the United States and its related issues are first discussed. Thereafter, 
findings from recent studies are explored, which are related to how the age of initiation of 
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marijuana, the amount of marijuana used, and the length of time during which marijuana 
was used appear to have an effect in the health effect of marijuana on the biological 
markers, including the serum level of ALT, AST, ALB, ALP, TB, TP and GGT. 
19 
 
Chapter 2: Literature Review 
Introduction 
The purpose of this literature review is to find articles related to the key variables 
of the study topic and use them to demonstrate that there is a significant gap in the 
literature regarding the predictors of the health effects of marijuana on hepatic function. 
In addition, this literature review serves as a broad overview of the new developments 
regarding the association between marijuana use and liver disease. This literature review 
also evaluates the role played by the key variables, including the age of participants, age 
of initiation, duration of marijuana use, and ALT, AST, ALP, TP, TB, ALB, and GGT in 
similar studies. 
Organization of the Review 
This literature review first presents an overview of the state of marijuana use and 
related issues in the United States. For a better understanding of the health effects of 
marijuana use on the liver, I also evaluate current studies on the possible association of 
marijuana use and liver diseases including NAFLD, hepatitis-C infection, liver fibrosis, 
and liver cirrhosis. I then provide an overview of liver diseases and risk factors. 
Additionally, after a brief review of the key variables, the literature review includes an 
evaluation of the role played by the age of participants, the age of initiation, the duration 
of marijuana use, and the dose of marijuana use in liver diseases. Finally, I examine the 
effect of marijuana use on the different outcome variables including ALT, AST, ALP, 
TP, TB, ALB, and GGT. 
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Literature Search Strategy 
Articles on the health effects of marijuana on hepatic function were found by 
searching online databases such as MEDLINE, CINAHL, and Google Scholar. I selected 
only peer-reviewed articles using keywords such as cannabis, marijuana, THC, pot or 
weed, liver, liver disease, liver function parameters, ALT, AST, ALP, TP, ALB, TB, and 
GGT. Multiple combinations of the keywords were used to identify potential articles on 
the association between the independent and outcome variables. Recent peer-reviewed 
articles on possible covariables were also identified using a combination of keywords, 
including alcohol, tobacco, liver, liver function parameters, and marijuana. I also 
identified several articles from the U.S. National Library of Medicine (NLM) and the 
National Institute of Health (NIH).  
A combined search of MEDLINE and CINHL limited to 2013-2019 using the 
keywords marijuana, cannabis, pot, weed, and THC, cross-searched with keywords liver 
disease, or liver failure, or liver cirrhosis yielded 78 peer-reviewed articles. The full-text 
articles identified narrowed the count down to 56 articles (42 articles in MEDLINE and 
14 in CINAHL). Among the 56 articles, 45 were considered relevant to the study either 
by elucidating the variables in the study or serving as a ground of possible association 
between predictors and response variables. The articles also served to demonstrate the 
existing gap or to make a case for the significance of the study. Through cross-searches 
using the same keywords in Google Scholar for the same period, I obtained 49 results 
consisting of articles and books. A combination of approximately 20 articles and books 
were considered relevant and introduced into the literature review. A search of the term 
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marijuana and the individual outcome variables (ALT, AST, ALB, ALP, TP, TB, GGT) 
yielded less than 15 results for each variable in MEDLINE and CINHL, which was also 
the case with the Google Scholar search. Approximately five articles per outcome 
variable were found to be relevant to the study. The same keywords were cross-searched 
in the U.S. NLM and NIH (PubMed) websites, and although some of the articles found 
had already been identified in the MEDLINE, CINHL and Google Scholar searches, I 
identified approximately 30 new relevant articles. A few articles related to the 
confounding variables through multiple combinations of the keywords alcohol, tobacco, 
marijuana and liver disease, liver failure, or liver cirrhosis were selected. 
Theoretical Foundation 
This study was grounded in the ecosocial theory introduced in 1994 by Krieger. 
The theory explains the cause of diseases, disease patterns, and disease distributions as an 
interconnected web of social and economic exposure through the course of the lives of 
the individual or population (Krieger, 2011). Unlike other disease etiology theories that 
connected disease occurrence to the interrelation between host-agent and environment 
(Egger, Swinburn, & Rossner, 2003), the ecosocial theory depicts a new 
multidimensional and more dynamic perspective of the cause of diseases, disease 
patterns, and disease distributions. The theory was based on four major propositions. 
The Core Propositions of the Theory 
The core propositions of the ecosocial theory are based on a multidimensional and 
dynamic perspective in the inquiry and analysis of the changing pattern of population 
health (Krieger, 2001). The first core proposition, embodiment, posits the idea that 
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human beings embody their life experiences, which, in turn, affect the disease patterns. 
The idea of embodiment is a recognition of the continued interaction between the human 
body and its environment. This interaction along the course of life is manifested at 
different levels and affects disease patterns. This interaction has a primary consequence 
of changing both gene regulation and expression (Krieger, 2001). The proposition of 
embodiment is that the determinants of disease patterns and distributions are exogenous 
to people's bodies and cannot solely be limited to the biological characteristics but also to 
the societal context (Krieger, 2001). The second core proposition of the theory suggests 
that there are multiple pathways of embodiment. The pathway of embodiment brings 
attention to the idea that specific exposures, including, for instance, exposure to toxic 
substances, social and economic precarity, cause poor health. The third core proposition, 
the joint interplay of exposure, susceptibility, and resistance, calls attention to the time it 
takes for the body to respond to the embodied materials, including change in gene 
expression. The fourth core proposition, accountability, calls on how health disparities 
should be monitored and analyzed. It also calls attention to the political and economic 
driving force of health-related issues, which represent grounds for the changing patterns 
in health.  
Ecosocial Theory and Marijuana Use  
The ecosocial theory has been used as grounds for inquiries in several social 
sciences, medicine, and environmental studies. Developed to address the question of 
“who and what drives social inequalities in health,” the theory has been central in 
facilitating inquiries about the changes in the population’s health patterns (Krieger, 
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2011). The theory has been used across different population groups including different 
age, gender, and ethnicity groups. Inquiries into the distribution in infectious, acute, and 
chronic disease have also seen the use of the ecosocial model. Epidemiological factors, as 
well as environmental factors, have been evaluated across multiple health issues using the 
ecosocial theory as a model of inquiry. Gomaa et al. (2016) assessed the cause of oral 
health inequality using the core proposition of the ecosocial theory, making the case that 
inquiries based only on biomedical and behavioral approaches to understand oral health 
inequality were ineffective. The authors analyzed a pathway through which social factors 
affected oral health outcomes, became embodied, and altered biological factors, including 
the expression of genes (Gomaa et al., 2016). The theory has also been a driving force in 
the development of new perceptions during illicit drug use inquiries (Duff, 2007; Ettorre, 
2004). For example, like Krieger (2005) who emphasized that the body tells stories, Duff 
(2007) studies drug use by the female gender and reported that the human body is a social 
identity and means of self-expression. Ettorre (2004) found that different factors were 
associated with drug use, including the cost of the drug, the availability of the drug, the 
level at which the body desires the drug, social exclusion, and the culture of the drug use 
which later, he stated, becomes embodied experiences. The first major proposition of the 
ecosocial theory, embodiment has been applied in different drug use, substance use, 
intoxication, and addiction studies, while also emphasizing the social and environmental 
context in which users live (Angus, 2013; Duff, 2007; Ettorre, 2004).  
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The Rationale of Choosing the Ecosocial Theory 
Human bodies often tell stories that may not be consistent with their assertion, 
and these stories should be studied in the context of the individual’s course of life 
(Krieger, 2005). The ecosocial theory explains disease patterns by emphasizing on social 
and biological interactions. In addition, several authors linked the predictors of drug use 
to social factors and the environment in which the users live (Angus, 2013; Duff, 2007; 
Ettorre, 2004). Consequently, understanding the predictors of marijuana use on the 
hepatic function required the examination of the user’s adverse factors exposure. In her 
theory, Krieger (1994) also stipulated that, once embodied, the adverse exposures altered 
gene expression as the source of diseases. In this study, the predictors once embodied 
may affect gene expression and alter hepatic function. In brief, exposure to illicit drugs 
such as marijuana is a potential pathway that affects the physiology and gene expression 
in certain users, which in turn, affects the condition of their health. Like many recent 
studies (Adejumo et al., 2017; D. Kim et al., 2017), the current study broke with studying 
disease burden while relying only on the biological factors. The examination of social 
and biological interactions during disease pattern inquiries helped to identify risk factors 
or potential predictors of the health effects of marijuana use on hepatic function. The 
embodiment and the pathways of embodiment constructs helped to understand how once 
embodied these risk factors altered the biology of gene expression, which can be the 
source of adverse health outcomes. The third construct, the pathway of the interplay of 
exposure, susceptibility, and resistance helped the study to frame the presence of 
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potential confounders and/or effect modifiers concerning risk factors assessment and 
analysis in marijuana users.  
The ecosocial theory not only provides a new perception in the study of potential 
effects of marijuana use on the liver but also guides to understand that during the human 
course of life, risk factors are embodied and altered the biology of gene expression, 
which are a source of diseases.  
Marijuana Use: State of the Problem 
Marijuana is the oldest and most widely used illicit drug in the world (NIDA, 
2015). Historically, it was available in the U.S. around 1900 (Chasteen, 2016), and as of 
2015, more than 11 million Americans used the drug (NIDA, 2015). With the increasing 
decriminalization of marijuana, it is imperative to reevaluate the health risks and health 
benefits associated with the drug. 
In recent years, there has been a change in perceived risk associated with the use 
of marijuana, and people who believe that marijuana use is associated with health risk is 
decreasing (Okaneku et al., 2015). Okeneku, et al. (2015) analyzed the data from 2002 to 
2012 from the National Survey on Drug Use and Health (NSDUH) and found a 
significant decrease in perceived risk in occasional and regular marijuana users. When 
the model was stratified by age, gender, and their past month of use, the study revealed 
that decreases in the perceived risk of marijuana use were associated with younger age, 
male gender, and past their month of use. The study associated such decreases in risk 
perception to the change in marijuana laws. There was a marginally significant increase 
in young adults’ acceptance of marijuana use because of the implementation of medical 
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marijuana laws and a perception that marijuana use has no or low risk (Wen, 
Hockenberry, & Druss, 2018). In Washington and Colorado, where recreational 
marijuana has been legalized, Washington has seen an increase in adolescent marijuana 
use when Colorado pre- and post-legalization saw no change (Cerdá et al., 2017). 
Marijuana use is on the rise compared to the other illicit drug use in the U.S. In 
2011, the Drug Abuse Warning Network (DAWN) reported 455,668 emergency 
department visits related to marijuana use, representing a 52% increase between 2004 and 
2011 and 36% of all non-alcohol illicit drug emergency department visits (SAMHSA, 
2014). In 2015, the SAMHSA reported 157,733 marijuana/hashish-related admissions in 
hospitals or residential service treatments. Overall, the prevalence of marijuana 
consumption more than doubled from 2001-2002 to 2012-2013 (SAMHSA, 2014). This 
significant increase has been observed across all population subgroups (sex, age, 
race/ethnicity, education, marital status, income, urban/rural, and region) (SAMHSA, 
2014). During that same period, there was a significant increase in marijuana use 
disorders (Hasin et al., 2015). Interestingly, between 1990-1991 and 2001-2002, the 
prevalence of marijuana was stable with an increase in marijuana use related disorders. 
This inverse result seen during the two-study periods suggested the presence of a new 
factor, which several scholars have associated with the increase in potency of marijuana. 
In fact, ElSohly et al. (2016) found that the THC potency in marijuana on the illicit 
market has consistently increased from approximately 4% in 1995 to 12% in 2014 .When 
assessing the issues related to such an increase in potency in illicit marijuana, Wolkow et 
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al. (2014) concluded that the health consequences of marijuana may be worse now than 
in the past. 
Although multiple studies have reported adverse effects from the use of 
marijuana, many other studies have found positive health effects from the use of the drug. 
Wolkow et al. (2014) published a report that addressed the adverse effects of marijuana 
use, including its effects on the brain development, the risk of cognitive impairment, 
altered mental health, diminished life satisfaction, poor educational outcomes, and the 
development of symptoms of chronic bronchitis. The report also acknowledges the health 
benefit of marijuana use, including its ability to relieve the symptoms of glaucoma, 
nausea, chronic pain, inflammation, multiple sclerosis, and epilepsy. However, Volkow 
and his colleagues suggested making better use of the medical benefits of marijuana to 
avoid exposing people who are sick to the intrinsic negative effects of the drug. 
Although some studies have reported beneficial health effects of marijuana, and 
other reported adverse health effects, the issues associated with the health effects of 
marijuana on the human body remain the subject of heated debates among scientist and 
policymakers. 
An Overview of Liver Diseases and Risk Factors 
The major causes of liver disease are related to a variety of factors, include an 
increase and continued consumption of alcohol, autoimmune disorders, viral infections, 
drug-related causes and non-alcoholic accumulation of fat in the liver cells. (Fumeaux et 
al., 2018; Wang, Fan, Zhang, Gao, & Wang, 2014). Common liver diseases are hepatitis 
B virus (HBV), HCV, alcoholic and nonalcoholic liver disease, cirrhosis and 
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hepatocellular carcinoma (Wang et al., 2014). The liver is the largest and the most 
important organ in the human body. It performs more than 500 vital functions that range 
from cleaning toxins from the blood and providing the body with nutrients to storing 
energy by participating in the metabolism of carbohydrate, lipid, and protein (Snyder, 
2016; Woldin, 2014).  
It is important to note that liver disease can be acute or chronic. Acute liver 
disease can develop into chronic. For example, viral hepatitis such as hepatitis A through 
E are considered acute viral diseases. However, Hepatitis B and C can progress into 
chronic hepatitis due to the continued and longtime inflammation of the liver (Snyder, 
2016). In addition, heavy alcohol consumption can also progress from acute liver disease 
to a chronic liver disease which is manifested by cirrhosis of the liver (Snyder, 2016; 
Woldin, 2014). In brief, three different scenarios can occur when someone is diagnosed 
with acute liver disease. Either the liver recovers from the acute inflammation process 
within a few weeks or few months or gets worse very quickly (fulminant hepatitis). In 
certain other conditions, acute liver disease can elevate to a chronic disease such as 
chronic hepatitis-C or cirrhosis (Snyder, 2016) which can lead to liver cancer or liver 
failure. 
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Figure 2. Liver diseases. 
Current Studies on Marijuana Use and Liver Disease 
Several studies in recent years are finding more about the positive health effects 
of marijuana (Adejumo et al., 2017; Kim et al., 2017). However, the question remains 
whether the health benefits of marijuana seen in recent years outweigh the negative 
health effects that have pushed U.S. health institutions and institutions around the world 
to consider marijuana as a Schedule I drug (SAMHSA, 2014). Findings of the health 
effects of marijuana on the liver vary from negative, positive, or no significant health 
effects, depending on preexisting liver conditions of the population studied (Kim et al., 
2017; Pateria, de Boer, & MacQuillan, 2013). Most of the researchers evaluated the 
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effects of the marijuana use on individuals with preexisting liver conditions such as 
NAFLD, hepatitis C, and liver cirrhosis and have found different results. 
The Effect of Marijuana on Nonalcoholic Fatty Liver Disease (NAFLD) 
NAFLD is an inflammation of the liver that is not caused by alcohol but by the 
accumulation of fat in the liver (Bull, 2013). NAFLD can progress into nonalcoholic 
steatohepatitis (NASH) which is more prone to the development of cirrhosis (Pattnaik et 
al., 2018). Possible risk factors are diabetes mellitus, metabolic syndrome, high blood 
pressure and hyperlipidemia (Al-Dayyat, et al., 2018; Pattnaik et al., 2018). With the 
increasing level of obesity, NAFLD has emerged as the most common chronic liver 
disease in the developed world (Ajmera & Loomba, 2017). With the exception of a few 
clinical studies published before 2010 (Purohit et al., 2010) that found that smoking of 
marijuana may be detrimental to the liver and increase the risk of developing NAFLD, 
most recent epidemiological studies are finding that the consumption of marijuana has a 
therapeutic effect on the health of the liver (Adejumo et al., 2017; Kim et al., 2017). 
When analyzed the function of the endocannabinoid system that comprises the CB1 and 
CB2 receptors, a clinical study found that marijuana use may be detrimental and 
constitute a risk factor for NAFLD (Purohit et al., 2010). CB1 and CB2 are 
phytocannabinoids receptors of THC, the principal cannabinoid compound found in 
marijuana (Mallat & Lotersztajn, 2010). CB1 and CB2 receptors play a key role in 
hepatic steatosis, hepatic inflammation, and liver fibrogenesis (Alswat, 2013). No recent 
population-based studies, at least up to and included in this review, have found 
detrimental effects of marijuana on NAFLD. Instead, several recent population-based 
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studies have found therapeutic health effects associated with marijuana on the liver of 
NAFLD patients. In a cross-sectional study, when exploring the 2014 National Inpatient 
Sample (NIS) data to analyze the possible association between cannabis use and NAFLD, 
Adejumo et al. (2018) indicated that cannabis use is associated with a significantly lower 
prevalence of NAFLD with an adjusted odds ratio of 0.82. The findings suggest that 
cannabis has a suppression or reversal effect on the development of NAFLD. These 
findings are in line with the study results conducted by Donghee et al. (2017). Both 
studies used different data, though they found the same therapeutic effect of cannabis as a 
result of their investigations. When using the NHANES data, Donghee et al. (2017) found 
that marijuana users were less likely to be suspected of having NAFLD with an odds ratio 
(OR) of 0.90 (95% CI: [0.82-0.99]), and 0.68 (95% CI: [ 0.58-0.80]), respectively, for 
past and current users. The analysis of age, gender, and an ethnicity-adjusted model of 
ultrasonography-diagnosed data also revealed an inverse association between NAFLD 
and marijuana with an OR of 0.75 (95% CI: [0.57-0.98]) for current users. A similar 
trend was observed when current light and heavy users were compared to non-users. The 
results of the study also strongly suggested that the inverse association observed is 
independent of BMI value, educational level, economic status, smoking status, alcohol 
consumption, diabetes, hypertension and current use of cocaine. This independent 
association of marijuana with NAFLD was also the result of a population-based study 
conducted by Adeyinka et al. (2017), which reported a lower prevalence of NAFLD in 
cannabis users utilizing the Nationwide Inpatient Sample (NIS) of the Healthcare Cost 
and Utilization Project (HCUP). In addition to comparing cannabis users to nonusers, this 
32 
 
latter study has differentiated between dependent cannabis users and nondependent 
cannabis users and found a dose-response effect of cannabis on NAFLD. Dependent 
cannabis users are less likely to have NAFLD when compared to nondependent cannabis 
users. Because alcohol is known as a predictor of a higher prevalence of NAFLD 
(Adeyinka et al., 2017), the analysis of cannabis use on NAFLD in alcohol-dependent 
and nondependent patients has indicated that only nondependent alcohol users gain the 
benefit of the therapeutic effect of cannabis use. 
The Effect of Marijuana use on Hepatitis C 
Like in NAFLD, patients with hepatitis-C infection can also advance to the 
fibrosis stage or liver steatosis (Liu et al., 2014). With knowledge of the health effects of 
substance abuse on the liver, several researchers also examined the health effects of 
marijuana on the liver of hepatitis-C patients, and interestingly found conflicting results.  
A recent Canadian study found that marijuana use is not a predictor of liver 
steatosis, inflammation or the advancement to the fibrosis stage in hepatitis-C patients 
using liver biopsy data of 550 patients with whom 159 individuals were self-reported 
marijuana users. Instead, the study found that the age of the patients, HIV seropositive 
status, and history of intravenous drug use were predictors to the advanced stage of 
fibrosis in hepatitis-C patients (Liu et al., 2014). Unlike the above study, while examining 
the NIS of U.S. adult patients infected with chronic hepatitis C virus, Adejumo et al. 
(2018) demonstrated that cannabis use reduced the incidence of cirrhosis caused by HCV 
infection. The study also demonstrated that cannabis use reduced the prevalence of 
cirrhosis due to HCV infection including a reduction in the prevalence of ascites, variceal 
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bleeding, hepatorenal syndrome, hepatic encephalopathy, portal hypertension, and 
jaundice. Overall, reduction in inpatient mortality, length of hospital stay, and total health 
care costs have all been associated with marijuana use in HCV infection patients 
(Adejumo et al., 2018).  
Marijuana and the Key Independent Variables 
This portion of the existing literature review examines the influence of the age of 
marijuana user, the age of initiation of marijuana use, the quantity and the duration of 
marijuana use on the health condition of the liver.  
Marijuana, the Age Factor, and Liver Disease 
The age of marijuana users and the age of onset of marijuana use are at the core of 
the discussions regarding the effects of marijuana on human health (Johnson et al., 2015). 
Age has been found to be a risk factor for many chronic diseases including liver diseases. 
For example, Cheng et al., (2013) found increased prevalence of metabolic syndrome and 
fatty liver disease among the elderly population. In the United States, there was a modest 
decrease in the prevalence of marijuana use from 1999 to 2009, yet there was a steady 
increase since 2009. During that same period, adolescent use of marijuana has also 
decreased (Johnson et al., 2015). However, the age-specific onset of marijuana use has 
varied throughout recent history. The percentage of adolescents who tried marijuana 
before the age of 13 years increased from 1991 to 1999 but has seen a steady decrease 
from 1999 to 2015 (YRBSS, 2017). When assessing how marijuana affects the 
prevalence of NAFLD in two different subgroups (< 40 vs. > 40), the study found that the 
younger population (less than 40 years old) who heavily used marijuana displayed a 35% 
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reduction in risk of prevalence of NAFLD compared to a 26% reduction in the older 
population (greater than 40 years old) (Kim et al., 2017). Contrary to the above findings, 
Kotan et al. (2017) presented the results of the effect of cannabis use on 34 cannabis 
users who used cannabis for the first time at age 21.8 years (SD 5.0); after an average of 
more than 30.5 months of use, the patients still displaying close to normal liver function 
parameters. In other hands, Quraishi et al. (2013) found that at the age of initiation of 
15.31 years (SD 4.7), and after using cannabis for more than 9.53 years (SD 8.06), 51% 
of cannabis dependent patients showed abnormal liver-related parameters. These findings 
suggested that the age of marijuana users, the age of initiation and the duration of the 
substance use introduced some degree of variation in the effects of marijuana use on the 
health condition of the liver.  
The Duration of Marijuana Use and Liver Disease 
Addressing the marijuana-related health issues requires a better understanding of 
how much and how long people use marijuana during their lifetime and the degree to 
which it was used (NIDA, 2018). Terry-McElrath et al. (2017) associated increased risks 
of negative health outcomes in 50 years old marijuana users with moderate or heavy 
long-term use of marijuana. As previously mentioned, Quraishi et al. (2013) and Kotan et 
al. (2017) have shown that the duration of cannabis use is a predictor of the impact on 
liver health associated with the use of marijuana. Kotan et al. (2017) have found no 
negative health outcome at a mean duration of cannabis use of 30.5 months whereas 
Quraishi et al. (2013) found detrimental health effects at a longer duration of cannabis 
use of 9.53 years (SD 8.06). In addition, a Sudanese case-control study showed a strong 
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correlation between the duration of marijuana use and liver enzyme activity. The study 
found a significant difference in the activity of the enzymes of the control group 
compared to the subject group using 120 samples (60 samples of abusers and 60 samples 
of control cases) (Mohamed et al., 2015).  
The Quantity of Marijuana Use and Liver Disease 
The quantity of marijuana use is another factor at the core of the health effects of 
marijuana on users (Terry-McElrath et al., 2017). Out of 14,080 NHANES participants, 
Donghee et al. (2017) found that 56.1%, 36.9%, and 7% respectively reported never used, 
used in the past, and current users of marijuana. Of the 7 percent who reported currently 
using marijuana, light users represented 4.9 %, while heavy users represented 2.1%. 
When the study assessed the association between dose-dependent marijuana consumption 
and suspected NAFLD, the prevalence rates of suspected NAFLD were 30.5%, 38.0 %, 
and 40.7 %, respectively, in current light users, past users and those individuals who 
never used. The results were consistent when ultrasonography diagnosed NAFLD data, 
with 23.2%, 29.4%, and 35.0%, respectively, in current light users, past users and those 
individuals who never used. In brief, it has become apparent that current or past 
marijuana use has been significantly associated with a lower risk of the suspected 
NAFLD. In addition, when the study assessed only current users, light users were 
reportedly inversely associated with NAFLD, while there was no significant association 
with heavy users due to the small number of heavy users among the participants. The 
results of this study were consistent with the results of a study conducted by Adejumo et 
al. (2017), which analyzed the association with NAFLD in three categories of users (non-
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cannabis users, nondependent cannabis users, and dependent cannabis users) using the 
2014 HCUP data of 5,950,391 participants. After adjusting for possible covariates, the 
study found a 43 % lower prevalence (AOR: 0.57[0.42–0.77]; p < 0.0001) of NAFLD in 
cannabis-dependent users compared to nondependent users, suggesting that heavy 
cannabis use has a positive effect factor on the prevalence of NAFLD. In addition to 
NAFLD patients, a study conducted in Canada found that in HCV positive patients, 
cannabis users have the lowest frequencies of liver cirrhosis when compared to nonusers. 
In a dependent and nondependent category comparison, the prevalence of liver cirrhosis 
decreased by 15 % and 48% respectively among nondependent and dependent users 
(Adejumo et al., 2018). By contrast, Liu et al. (2014) found no significant difference in 
biopsy fibrosis, liver inflammation, and steatosis in 21 HCV positive patients classified as 
“high daily marijuana users” (> 1 g /day for marijuana use) compared to non-current 
marijuana users. Terry-McElrath et al. (2017) also demonstrated that the intensity of 
marijuana smoked is a strong predictor of negative health outcomes at 50-year-old 
individuals. 
Marijuana and the key outcome variables 
The liver function test consists of testing the level of ALT, AST, the level of 
ALT/AST ratio (LSR), TB, GGT, and LDH in a serum sample (Huang, et al., 2017). 
Several other studies also introduced ALB, TP and ALP as part of the liver function test 
(Fumeaux et al., 2018). 
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ALT and Marijuana 
ALT is a circulating transaminase in the human body and a specific marker for 
liver dysfunction (Huang et al., 2017). The enzyme activity is influenced by clinical 
factors including hepatitis-related diseases, alcohol consumption, disease states such as 
NAFLD, and certain medications and physiological factors such as extreme physical 
exertion (Z. Liu, Que, Xu, & Peng, 2014). Socio-demographic factors such as age, 
gender, and ethnicity may also interfere with the enzyme activity (Kim et al., 2017; Ruhl 
& Everhart, 2012). Although the enzyme is measured to assess overall health (Z. Liu et 
al.,2014), the elevated level is often observed in liver dysfunction meaning that the 
enzyme is more specific to liver disease (Marshall et al., 2014). Per Mohamed et al. 
(2015) chronic marijuana use is associated with the hepatic enzymatic alteration. 
Mohamed et al. (2015) conducted a case-control study of 60 people with a history of 
cannabis use and 60 samples in a control group. Age and sex were matched with age 
ranging from 18 to 60 years old. The study excluded people with liver cirrhosis, hepatitis, 
jaundice, hepatomegaly, and liver carcinoma and found a significant statistical difference 
in ALT between the two groups. The study concluded that cannabinoids are possible 
hepatotoxic substances. By contrast, Kotan et al. (2017) found a normal ALT level (mean 
28.4, SD 18.9, normal ALT < 45) in 118 Indians male cannabis users who used cannabis 
for more than 30 months. In cannabis-dependent users, Quraishi et al. (2013) also found 
that, although it is difficult to solely isolate cannabis-dependent subjects, cannabis-
dependent with co-morbid substance use showed an elevated ALT level in 51 subjects 
with a 17.6% increase compared to the control group. Contrary to its toxicity effect 
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presented in non-liver disease patients, cannabis may have a therapeutic effect by 
normalizing the level of ALT in NAFLD (Kim et al., 2017). In a cross-sectional study, 
Kim et al. (2017) found a statistically significant difference in ALT levels between 
current cannabis users and past users and those individuals who never used cannabis who 
are suffering from NAFLD. Heavy cannabis users with NAFLD showed a normal low 
ALT level (28.0 SD 2.0, p < 0.001) compared to light users (30.5 SD 0.8, p < 0.001). A 
significant statistical difference has also been seen in the ALT levels across gender 
between current, and past users and those who never used presenting with NAFLD.  
AST and Marijuana 
Like ALT, the serum level of AST also increases during liver dysfunction. 
However, AST is less specific to the liver compared to ALT. Apart from being elevated 
in liver diseases, the activity of the enzyme is also influenced by the state of particular 
disease such as in myocardial infarction, muscular dystrophy, pulmonary emboli, and in 
acute pancreatitis (Marshall et al., 2014).  
Demographic factors such as age, gender and ethnicity are also important when 
evaluating the activity of AST (Kim et al., 2017; Ruhl & Everhart, 2012). It is also 
known that marijuana alters the effect of AST (Mohamed et al., 2015). Mohamed et al. 
(2015) elucidated in a case-control study involving 60 subjects that the AST level in 
marijuana users is significantly different compared to the control group in a Sudanese 
population. The study then concluded that a possible alteration effect of marijuana on 
AST exists. Contrary to the above finding, Kotan et al. (2017) discovered a normal level 
of AST (31.2, SD 22.0, Normal AST < 37) in 118 Indians male cannabis users who used 
39 
 
cannabis for more than 30 months. In another case-control study, Quraishi et al. (2013) 
found that cannabis dependent users with comorbid substance use had elevated AST 
activity with 33.33% of the study subjects showing abnormal values of AST. By contrast, 
Rahmayanti et al. (2017) revealed that most of the patients who used cannabis and other 
drug exhibited normal AST levels. The study evaluated cannabis use with comorbid drug 
users in more than 823,810 cases with more than 50% using cannabis and found that most 
of the subjects (88.83%) displayed within normal range serum AST level. Only 1.12% of 
participants showed below normal range AST level, and 11.6% of the participants 
displayed AST levels that are above the normal range. Other studies like the one 
conducted by Muniyappa et al. (2013) found no effect of cannabis on AST. In a cross-
sectional, case-control study, involving 30 cannabis smokers (12 women, 18 men, 
Average age = 27 years, SD 8 ) and 30 control subjects matched for age, sex, ethnicity 
and BMI, Muniyappa et al. (2013) found no statistical difference between the AST of 
cannabis smokers and nonsmokers (control group).  
ALP and Marijuana 
ALP is another enzyme used as part of liver function tests to evaluate possible 
dysfunction of the liver (Bishop et al., 2018; Lowe & John, 2018). A non-specific 
enzyme, 80% of ALP found in the serum originates from the liver and bones and in small 
amounts from the intestine. In most adult patients, an elevated ALP is an indicator of 
liver disease (Lowe & John, 2018). The clinical significance of ALP activity lies in the 
diagnostic of cholestatic liver disease (Bishop et al., 2018). The enzyme serves as a 
marker of extrahepatic cholestasis such as stone in the bile duct or intrahepatic 
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cholestasis such as drug-induced cholestasis or biliary cirrhosis (Bishop et al., 2018; 
Lowe & John, 2018; Sharma et al., 2014). However, the interpretation of ALP is difficult 
because variation in the enzyme activity can occur in different liver conditions including 
liver cirrhosis, chronic hepatitis, viral hepatitis and in the absence of liver damage such as 
congestive heart failure, related bone disorders and in primary and metastatic cancer 
(Bishop et al., 2018; Lowe & John, 2018). Age, gender, and ethnicity are demographic 
factors associated with variations in ALP activity. The ALP level is slightly higher in 
men compared to women, and it decreases in the 15 to 50 age group, then and increases 
again in the old age (Lowe & John, 2018). A positive association has also been found 
between ALP body weight and smoking (Bishop et al., 2018; Lowe & John, 2018). 
Marijuana has been shown to be strongly correlated with an increase in ALP level in a 
case-control study in the Sudanese population using 60 patients who used cannabis for 
more than ten years matched with 60 controls non-smoker subjects. Chronic smokers 
showed a significant increase in ALP compared to non-smokers (Mohamed et al., 2015). 
A study conducted in India in 34 cannabis users (mean duration of cannabis use was 30.5 
months; SD 31.8) showed normal ALP serum level (Mean ALP = 73.4, SD 30.0; ALP 
normal < 136; Kotan et al., 2017). Contrary to the above finding, Quraishi et al. (2013) 
found a significant increase in ALP in cannabis-dependent subjects pointing to an 
abnormality in liver function due to cannabis use. A total of 51 substance-using subjects 
with a mean duration of cannabis use of 9.53 years (SD 8.06 years) and 30 control 
subjects were used during the study. Findings revealed an elevation of 37.25% in 
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substance-using subjects compared to the control group (control group 98.82, SD 26.46; 
subjects’ group 217.53, SD 95.84., p < 0.05) 
TB and Marijuana 
Bilirubin is a breakdown of old and damaged red cells collected in the liver. 
Sometimes the body can have an excess of bilirubin, a condition called 
hyperbilirubinemia and recognized as jaundice (yellow discoloration of the skin, eyes and 
mucous membranes) when the excess is accumulated in the tissue (Bishop et al., 2018). 
Clinical conditions including liver disorders, liver infections such as hepatitis, cholestasis 
and Gilbert syndrome may increase the level of bilirubin in human serum. However, 
medications, such as phenobarbital and theophylline, contribute to lower levels of 
bilirubin in the human body (Bishop et al., 2018; VanWagner & Green, 2015).  
Bilirubin is part of a liver function test to evaluate a possible disorder of the liver 
(Bishop, 2018). Factors other than liver disease may cause an increase in bilirubin. So, it 
is important to know the etiology of the Jaundice, (VanWagner & Green, 2015; Bishop, 
2018). In prehepatic jaundice such as in acute and chronic hemolytic anemia and post-
hepatic anemia including gallstones and tumors, the liver should be ruled out as the 
primary cause of the increased level of bilirubin (Bishop, 2018). In hepatic jaundice, the 
primary cause of elevated bilirubin is due to liver diseases or disorders related to bilirubin 
metabolism and transport which are functions intrinsic to the liver (Bishop, 2018). 
Among factors that increase the level of bilirubin, cannabis is a contributing factor. In 
India, a case-control study involving 250 male subjects (125 cannabis abusers and 125 
control group) found a significant difference in the mean value of TB when the two 
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groups were compared. Cannabis abusers exhibited a TB value of 14.78 (SD 3.10) 
compared to 11.1 (SD 3.23) in the control group (Wani et al., 2017). However, in a cross-
sectional study involving 34 cannabis users (Average age 21.8 years, SD 5.0; duration of 
cannabis use 30.5 months, SD 31.8), Kotan et al. (2017) showed that cannabis users 
presented a normal value TB levels (normal TB: 0.3- 1.2 mg/dl). By contrast, Quraishi et 
al. (2013) found that the consumption of cannabis increases the level of serum bilirubin 
by 13.72% compared to noncannabis users using a case-control study in 30 control 
subjects and 51 cannabis dependent subjects (Average age of initiation 15.31 years, SD  
4.7; duration of cannabis use  9.53 years SD 8.06). 
TP and Marijuana 
The serum TP, which is mainly synthesized by the liver, is of great importance 
because it serves in the regulation of several physiological functions, maintaining the 
osmotic pressure, transport of various metabolites, and participation in the activity of the 
immune system (Bishop, 2018). The level of serum TP gradually decreases with age and 
varies across gender (Tian, Qian, Shen, Li, & Wen, 2014). The evaluation of serum TP is 
useful to assess the synthetic ability of the liver. Although the protein level is not a 
sensitive marker for liver damage, its useful in quantifying the severity of liver 
dysfunction (Bishop et al., 2018). Findings of the health effect of marijuana on the Total 
serum protein in adults varies across studies. A case-control study conducted in India 
which assessed the level of serum TP in 125 cannabis abusers, compared 125 non-
cannabis smokers and found a decreased level of serum TP in cannabis abuser compared 
to non-smokers (Wani et al., 2017). Unlike the previous study, Quraishi et al. (2013) 
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found in another case-control study involving 51 cannabis-dependent participants and 30 
control subjects that smoking cannabis increased the level of serum TP by 15.68%. 
ALB and Marijuana 
Synthesized by the liver, albumin is the major type of protein in human serum. It's 
involved in maintaining proper osmotic pressure and in the transport of various 
substances through the body (Bishop et al., 2018; Morman & Varacallo, 2018). A low 
concentration of albumin is most commonly associated with potential liver disease 
(Morman & Varacallo, 2018). Illegal drug use such as cannabis has been shown to 
decrease the level of albumin in human serum. In a recent case-control study, Quraishi et 
al. (2013) demonstrated the presence of a low albumin level in cannabis dependent 
patients compared to non-users with a mean duration of cannabis use being 9.53 years 
and the mean age of initiation being 15.31 years. Like the previous study, Wani et al. 
(2017) also found a lower score of albumin level in cannabis users compared to non-
users. In a different cohort, with age of initiation 21.8 years and the duration of cannabis 
use being 30.5 months, Kotan et al. (2017) found a normal level of albumin in 34 
participants with average ALB level of 4.20g/dl (SD 0.6, normal range 3.5-5.2g/dl). 
GGT and Marijuana 
Elevated activity of GGT is found in liver dysfunction, hepatobiliary disorders 
and chronic alcohol consumption (Koenig & Seneff, 2015; Bishop., 2018). Drugs such as 
warfarin, phenobarbital, and phenytoin are noted to increase the enzyme level. Marijuana 
consumption is also noted to affect the level of GGT. Wani et al. (2017) noted in a case-
control study of 250 male participants (125 cannabis abusers and 125 control group, 
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mean age 25.32 years) that cannabis abusers exhibited a higher level of GGT compared 
to non-users. However, 34 participants with a mean age of 21.8 years who use cannabis 
for 30.5 months (SD 31.8), exhibited a normal level of GGT of an average 24.6 (SD 13.1, 
Normal range < 55 u/l; Kotan et al., 2017). 
Summary of the Literature Review 
Four major factors are at the core of the increasing health problems associated 
with marijuana, including: (1) increasing decriminalization of the drug, (2) decrease in 
perceived risks seen in young male subjects, (3) increase in potency of illegal marijuana 
from 4 to 12% in recent years, and (4) the increased prevalence of marijuana 
consumption, which has more than doubled in recent years. Despite these four core 
issues, epidemiological study findings of the health effects of marijuana are conflicting. 
Several studies reported the therapeutic effect of the drug with respect to certain diseases, 
while others are still warning about its adverse health effects and have recommended 
more epidemiological investigations.  
It is important to point out that in this literature review, the health effect of 
marijuana on the liver has been more studied on individuals with preexisting liver 
conditions including NAFLD, NASH, and hepatitis-C. The available literature on the 
effect of marijuana on the liver of healthy participants is rare.  
Finally, several studies have shown that the quantity of marijuana smoked, the age 
of initiation and the duration of marijuana use are critical factors in assessing the health 
effects of marijuana on the liver. These studies revealed that marijuana consumption 
causes some variations in the enzymatic activity of the liver. 
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Chapter 3: Research Method 
This chapter provides explanation for the different steps in the data analysis 
process from the data collection to the testing of the above hypotheses. I explain the 
rationale of the epidemiological design chosen to guide the study, the sampling 
procedure, the data collection procedure, and how the variables were measured and 
coded. Finally, Chapter 3 presents the data analysis plan, which includes a procedure for 
how the dataset was cleaned to make it appropriate to analyze and how the hypotheses 
were tested. The data analysis plan gives an overview of all assumptions necessary to use 
Linear regression analysis to test the hypotheses 
Study Design and Rationale 
Study designs are key factors needed to appropriately address the study questions. 
Choosing an inappropriate study design has the potential to undermine the study validity, 
which is critical in determining the scientific value of any effective research study 
(Munnangi & Boktor, 2018). Thorough planning and accurate identification of study 
factors and study subjects are important in selecting an adequate study design (Szklo & 
Nieto, 2014). The goal of this section is to explain the ground on which a cross-sectional 
study design is chosen to elucidate the study questions and how it is to be applied to 
answer the study questions. In addition, the advantages and disadvantages of using a 
cross-sectional study design in the context of the project are also presented. To 
understand the relation between the disease factors and specific behavior in group of 
people, or the cause of diseases, or the disease patterns, epidemiologic scholars 
established specific epidemiologic study designs that helps to appropriately address 
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possible questions during epidemiological events (Friis & Sellers, 2009; Munnangi & 
Boktor, 2018; Szklo & Nieto, 2014).  
As stated previously, I designed this study to evaluate the predictors of the health 
effects of marijuana on the hepatic function. The study addresses the question of whether 
the dose of marijuana use, the age of initiation of marijuana use, and the duration of use 
are associated with liver dysfunction. Three independents variables, seven dependent 
variables, and four controlled variables were manipulated to answer the study questions. 
The independent variables included the number of joints or pipes smoked daily, the age 
of initiation, and the duration of marijuana use. The dependent variables were the liver 
function parameters, which comprise the serum level of ALT, AST, ALB, ALP, TB, TP, 
and the GGT. The four controlled variables were the age of the participants, their gender, 
the average alcohol consumed daily and the BMI of the participants. 
An effective study design depends on the intent of the investigator, the unit of 
analysis and the time dimension (Friis & Sellers, 2009; Szklo & Nieto, 2014). For 
instance, if the investigator is willing to control the exposure of interest, the best option to 
address study questions is to opt for experimental study design. Otherwise, the 
observational study design is more appropriate (Friis & Sellers, 2009). In an experimental 
study design, the investigator has control over the research setting and randomly assign 
subjects to the exposed and non-exposed group (Friis & Sellers, 2009). Contrary to the 
experimental study design, in an observational study, the investigator has no control over 
the circumstances in the research setting and does not control the exposure of interest or 
manipulate the study subjects (Friis & Sellers, 2009; Munnangi & Boktor, 2018; Szklo & 
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Nieto, 2014). The observational study design moves closer to the cross-sectional study 
design. Depending on the unit of analysis and the temporal dimension of the study, an 
observational study design can be subcategorized into a cohort study, case-control study 
and a cross-sectional study (Babby, 2017; Munnangi & Boktor, 2018). In all three study 
designs, the exposure is measured at the individual level. In cross-sectional study designs, 
the exposure and disease are measured at the individual level at a single point of time 
(Friis & Sellers, 2009; Munnangi & Boktor, 2018, Szklo & Nieto, 2014). Cross-sectional 
studies, used to assess the prevalence of the disease in a population, do not require a 
follow-up period and cannot provide a cause-and-effect relationship (Munnangi & 
Boktor, 2018).  
The dataset used in this study was self-reported data, which includes exposure and 
outcome information at an individual level at a specific point of time. For that reason, it 
was more appropriate, in the case of these types of data to explore a cross-sectional study 
design to answer the study questions. Furthermore, the intent of this study was not to 
establish a cause-and-effect relationship but to assess a possible association between 
predictors of the health effects of marijuana and hepatic function. Correlation data 
analysis is an appropriate tool to evaluate such an association. According to Lau (2017), 
the correlational study can be used to determine the prevalence and to predict future 
events based on known data. A correlational study is more concerned about establishing a 
relationship between exposure and outcome variables without any attempt to influence 
them (Asamoah, 2014; Lau, 2017). In correlational studies, researchers need to identify 
the study variables, establish study questions and hypotheses, select appropriate sample 
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and data, calculate correlation, and finally report and interpret results (Asamoah, 2014; 
Lau, 2017). In this study, the variables, the study questions, the hypothesis, and the data 
source have already been mentioned. However, the statistical technique that allowed 
establishing possible correlation has not yet been adequately addressed.  
This study, I used statistical techniques to test the hypotheses that answered the 
study questions. The choice of statistical techniques that adequately answered the study 
questions depended on the sample size, the type of research questions being asked, and 
the scale of measurement (Nayak & Hazra, 2011). The choice of linear regression to test 
the hypotheses in this study was based on two major factors. First, the goal was to 
establish a relationship between two or more variables, and secondly, the outcome 
variables were continuous variables. Assuming that all other assumptions were met, the 
two factors mentioned above were sufficient to adequately use linear regression. In this 
context, data were collected using multistage sampling techniques. So, instead of using a 
standard multiple regression, a complex sample general linear model (CSGLM) was used 
in SPSS to analyze the data. The CSGLM procedure performs linear regression analysis, 
as well as analysis of variance and covariance, for samples drawn by complex sampling 
methods (International Business Machines [IBM], 2017) 
Stated simply, this study was an observational cross-sectional study by nature, 
which used a linear regression model to test the hypotheses. It is important to note that 
the study can only suggest that there is a relationship between two or more variables, it 
cannot imply causality. 
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Multiple Linear Regression 
The regression model is important to describe the relationship between an 
outcome variable and one or more independent variables (Hosmer et al., 2013). Linear 
regression is used for that same purpose. It allows to prediction of variability in an 
outcome variable based on other variables (Kutner, 2004) However, linear regression 
differs from other regression models as it examines the association between one or more 
independent variable that are continuous or categorical and one continuous outcome 
variable (Kutner, 2004).  The model follows the equation 
  =  +  +  +⋯+ 

 
Where: Y is the expected value of the independent variable 
 x1 through xi are i distinct independent or predictor variables 
 b0 is the value of Y when all of the independent variables (x1 through xi) 
are equal to zero 
 b1 through bi are the estimated regression coefficients 
Each estimate regression coefficient represents the change in the dependent 
variable for a one-unit change in the corresponding independent variable, holding all 
other independent variable constant (Kutner, 2004). 
Methodology 
The Study Population 
The study population was drawn from the NHANES data from 2009 to 2016 data 
cycles. The NHANES contains health data from representative U.S. residents, or more 
specifically, the civilian noninstitutionalized U.S. population. The survey comprised 
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household sample screening, interviews, and physical examinations (NCHS, 2015b). 
Although the NHANES contains data on all health-related issues and all ages, I drew the 
sample for this study from participants aged 20 to 59 years old who have had contact with 
marijuana or hashish. I excluded the population sample with a history of HBV and HCV 
infections.  
The NHANES relied on questionnaires and examination surveys to select and 
collect data on the target population. For the present study, questionnaires related to the 
age of the participants, the age at which the participants first tried marijuana or hashish , 
the time since the participants last used marijuana, the number of joints or pipes the 
participants use in a day, and how often the participants use marijuana were critical in 
compiling the study sample. Liver function test results performed in the laboratory on 
participant's blood samples during the physical examination process were also part of the 
study sample. These laboratory tests included the blood serum level of ALT, AST, ALB, 
TP, TB, ALP, and GGT.  
Sampling and Sampling Procedures 
The NHANES, conducted by NCHS at the Centers for Disease Control and 
Prevention (CDC) gathered health information on the U.S. noninstitutionalized 
population including the U.S. 50 states and the District of Columbia. The survey 
excluded people in custody in an institutional setting, all active-duty military personnel, 
active-duty family members living overseas, and all other U.S. citizens living outside of 
the U.S. (Johnson, Dohrmann, Burt & Mohadjer, 2014). 
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Established in 1970, the NHANES has evolved since 1999 to become a 
continuous health data collection program that collects data and releases data on a two-
year cycle (NCHS, 2015a). The survey consists of a household screening, an interview 
process, and a physical examination at a medical examination center (MEC; Johnson, 
Dohrmann, Burt, & Mohadjer, 2014). The household screen determines if the household 
is eligible for an interview and a physical examination. The interview process collects 
person-level data on demographic factors, health, and nutrition information as well as 
household information. The third step that includes a physical examination helps to 
collect data on the participant's blood pressure, dental health status, and to collect blood 
samples for laboratory testing (Johnson et al., 2014). The NHANES gathered the health 
data through a complex multistage probability sampling design. The first stage is 
selecting the Primary Sampling Units (PSU) from all counties in the U.S. (NCHS, 
2015b). In some cases, due to sample size requirements, some small counties or adjacent 
counties may be combined (Johnson et al., 2014). The second stage consists of selecting 
area segments comprising census blocks or combinations of census blocks containing 
cluster of households designed to produced equal sample size per PSU. (NCHS, 2015b). 
The third stage consists of selecting specific households and dormitories within each 
segment. The fourth stage consists of selecting persons in each sampled household. 
(Johnson et al., 2014). The NHANES oversampled some specific race, age, sex, and 
income subgroups to increase the precision rate (NCHS, 2015a; Johnson et al., 2014). For 
example, in the latest NHANES (2015-2016), Hispanic persons, non-Hispanic black 
persons, non-Hispanic Asian persons; non-Hispanic white and other persons who 
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reported race other than black, Asian or white aged 80 years and older and persons below 
185% of the U.S. Department of Health and Human Services (HHS) guidelines were 
oversampled (NCHS, 2015a). Every year, the expected annual sample size is 6888 
persons with 5000 participants expected to have the physical examination (Johnson et al., 
2014). In the 2015-2016 survey cycle, the latest data cycle released, 15,327 persons were 
selected for NHANES from 30 different survey locations. Of those selected, 9,971 
completed the interview and 9,544 were examined (NCHS, 2015b). 
For the current study, the sample was compiled from the NHANES data from the 
2009-2010 survey cycle to the 2015-2016 survey cycle which is a combination of 4 
survey cycles over eight years of data collection. As part of this study, the sample 
selection was based on the participants who answered the drug questionnaire: “have you 
ever used marijuana or hashish.” All participants who were 20 -59 years old, males or 
females, who answered “YES” to the drug-using questionnaires were included in the 
study. However, to reduce bias, I applied some exclusion criteria. Only the participants 
who used marijuana or hashish within the last 30 days of the survey were included and, 
people with severe hepatitis B and C disease were excluded from the study. 
Sample Size Justification 
Software such as G*Power, and SPSS sample power are available to evaluate the 
minimum sample size required to obtain acceptable power for a study validation. 
Although this software make the calculation of minimum sample size easy and less time 
consuming, multiple regression using the G*Power to determine the actual sample size 
required the R2 (percentage of variability in the outcome variable that is explained by the 
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predictor variables). At this point in the study, these required data are not yet available. 
However, G*Power offers a priori calculation of the sample size base on the anticipated 
effect size, the desired statistical power and the number of predictors and an estimated R2 
of .5.  
In this study, the calculation of the minimum sample size using the F-statistical 
test for multiple linear regression (Fixed model, R2 deviation from zero) in G*Power 
yielded a sample size of 153. It’s important to note that the calculation was performed 
following the established guideline of G*Power 3.1.7 (Faul et al., 2013) with alpha 0.05, 
a power of 0.95, and a medium effect size of 0.15 and R2 of .5. for three predictor 
variables. A posthoc analysis of sample size was performed when data became available.  
Data Collection Procedures 
Started in 1960, the NHANES was designed to access the health status of the 
American people of all ages with various health conditions (NCHS, 2015a). From 1999, 
the survey started collecting data continuously and included nutritional risk factors as part 
of its inquiries (NCHS, 2015a). Each year, the survey sampled more than 5000 
participants located in different counties across the United States (Johnson et al., 2014). 
Using the multistage sampling process to identify potential candidates, the survey 
followed three steps. The prescreening process helped to identify if a household qualifies 
for the interview process. The interviews were carried out at the participant's home by 
trained health professionals using the Computer-Assisted Personal Interview (CAPI) on 
questions related to sociodemographic, dietary health, and general health is a very 
delicate part of NHANES operations (NCHS, 2015b). The interviews were followed by a 
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physical examination at the MEC. Three MEC are often active in a given time in the U.S. 
which were designed to cover the 15 counties selected during any survey period (NCHS, 
2015a). During the examination surveys, on top of conducting a dental, medical, 
physiological examinations and laboratory tests, the health professionals also gather data 
on the prevalence of chronic conditions on the participants. Data on risk factors 
associated with the participant's lifestyles, environmental factors, and hereditary 
conditions are also collected. Cigarette and tobacco smoking, alcohol consumption, drug 
use status, sexual practice, physical activities, reproductive health, contraception, 
breastfeeding practice, weight, and dietary intake data are also collected during the 
medical examinations (NCHS, 2015a). 
The local health and government officials in an upcoming survey area are notified 
ahead of the survey. The participants receive letters from the director of the NCHS to 
introduce the survey (NCHS, 2015a). To increase and facilitate participation, the 
NHANES provide transportation to and from the MEC. Participants also receive 
compensation and a report of the medical examination findings. The Unique feature of 
the NHANES compared to other surveys in the US is the collection of the medical 
examination data on each participant. For that reason, the operation at the MEC is 
carefully designed (NCHS, 2015a). An average of approximately 450 persons are 
examined in each of the 15 locations during every survey cycle. To minimize cost and 
increase the response rate, the survey is set up to sample a larger number of persons 
within a selected household (NCHS, 2015a). 
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The NHANES data have been used in several instances to develop and monitor 
nutrition and health programs across the US. research organizations, universities, and 
health care providers. Health educators benefited from the NHANES data to study key 
health issues, monitor and develop health programs, implement awareness programs and 
reduce health-related risk factors (NCHS, 2015a). The NHANES data have been key 
factors in establishing a growth chart that was used nationally by pediatricians. The data 
have also been instrumental in the implementation of policy that contributed to the 
reduction of the level of lead in food and canned soft drinks (NCHS, 2015a). The trend in 
overweight prevalence, policy, and related programs and awareness were initially linked 
to NHANES data. National programs to reduce hypertension, cholesterol and 
undiagnosed diabetes have found their root in the NHANES data (Division of Nutrition, 
Physical Activity, and Obesity, 2014).  
Gaining Access to the Data 
The NHANES data were available at no cost on the CDC’s website. All related 
documentations, including questionnaires, physical examinations, laboratory protocols, 
recommendations on analytical techniques were also available. The data were available in 
SAS format and need to be exported in the appropriate software format.  
Variables Operationalization, Measurement, and Coding 
Independent variables. 
 Number of joints or pipes of marijuana use daily was measured using the 
responses to the question “During the time you smoked marijuana or hashish, how many 
joints or pipes would you usually smoke in a day?” The answers were collected on a scale 
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of 1 per day, 2 per day, 3-5 per day, and 6 or more per day. The term marijuana included 
all forms of the drugs known as pot or grass either smoked as a cigarette (joints) or in a 
pipe or cooked. Hashish is a form of marijuana known as “hash” or hash oil. For analysis 
purposes, the categories 1 per day, 2 per day, 3-5 per day, and 6 or more per day were 
used as defined.  
Age of initiation was measured using the responses to the question “How old were 
you when you started smoking marijuana or hashish at least once a month for one year? 
The answer to this question is known in NHANES as the age at which the participants 
started regularly smoking marijuana. In regard to this study, the age of initiation was the 
age at which someone started and continued regularly using marijuana. I relied on the 
recommended age categorization from the United Nations (UN) which was categorized 
into five groups, including under 15, 15-24, 25-44, 45-64, and 65+ (UN, 1982). For this 
study, I recoded the above categories into three categories, including teen (under 15 years 
old), youth (15 to 24 years old), and adult (25 to 59 years old).  
Duration of marijuana use is the period in a lifetime when marijuana was used. 
The duration of marijuana used was calculated by subtracting the age since marijuana 
was last used from the current participant age. To account for only current users, I 
excluded any participants who had not used marijuana during the last 30 days from the 
analysis. The calculation of the duration of marijuana use also assumed that the 
participants continuously used marijuana since their time of the first contact. The age 
since marijuana was last used was measured in the NHANES by asking the question 
“How long has it been since you last smoked marijuana or hashish at least once a month 
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for one year?”. For this study, I categorized the duration of marijuana use into five 
groups: under 10 years, 10 to 19 years, 20 to 29 years, 30 to 39 years, and greater than 40 
years.  
Dependent variables.  
ALT levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling ALT levels were tested on approved calibrated 
instruments. The normal range for ALT expressed in international units per liter (IU/L) 
for males and females aged 20 years and older was 11 to 47 IU/L and 7- 30 IU/L 
respectively.  
AST levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling, AST levels were tested on approved calibrated 
instruments. The normal range for AST expressed in international units per liter (IU/L) 
for males and females aged 20 years and older was 13 to 33.  
ALB levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling, ALB levels were tested on approved calibrated 
instruments. The normal range for ALB expressed in gram per deciliter published by 
NHANES for males and females aged 18 years and older was 3.7 to 4.7 g/dL.  
ALP levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
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appropriate storage and handling ALP levels were tested on approved calibrated 
instruments. The normal range for ALP expressed in international units per liter 
published by NHANES for males and females aged 18 years and older was 36 to 113 
IU/L.  
TB levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling TB levels were tested on approved calibrated 
instruments. The normal range for TB expressed in milligrams per deciliter (mg/dL) 
published by NHANES for males and females aged 18 years and older was 0.2 to 1.3 
mg/dL.  
TP levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling, TP levels were tested on approved calibrated 
instruments. The normal range for TP expressed in grams per deciliter (g/dL) published 
by NHANES for males and females aged 18 years and older was 6.4 to 7.7 mg/dL.  
GGT levels were determined using laboratory standard testing methods. Collected 
plasma and serum samples were sent to the approved laboratory for testing. After 
appropriate storage and handling, GGT levels were tested on approved calibrated 
instruments. The normal range for GGT expressed in International Units per Liter (IU/L) 
published by NHANES for males and females aged 18 years and older was 10 to 65 IU/L 
and 8 to 36 U/L respectively.  
Control variables. 
59 
 
 Alcohol use was measured through the question “In the past 12 months, on those 
days that you drank alcoholic beverages, on average, how many drinks did you have?” 
One drink was defined as 12 oz of beer, 5 oz of wine, or 1.5 oz of liquor with one 
alcoholic drink equivalent to any beverage containing 14 g of pure alcohol (Office of 
Disease Prevention and Health Promotion [ODPHP], n. d.). Following the dietary 
guidelines for the year 2015-2020, I categorized alcohol consumption into light drinkers 
(less than 2 drink per day), moderate drinkers (2 to 4 drinks per day) and heavy drinkers 
(4 or more drinks per day).  
BMI is a calculation of the weight in kilograms divided by the height in meter 
squared. The weight and height were measured during the examination survey. The BMI 
was categorized following the guidelines recommended by the National Heart, Lung, and 
blood Institute (NHLBI, n.d.) where less than 18.5 was defined as underweight; between 
18.5 and 24.9 as normal weight; 25 to 24.9 as overweight; and 30 or greater as obese. 
Age: In the context of this study, age refers to the age of the participants at the 
date of screening. 
Gender: In this study, the gender of the participants can be male or female. 
Data Analysis Plan 
I used the IBM SPPS statistic version 25 to analyze the data. The NHANES data 
was initially published in SAS software format. The SPSS 25 was used to import the data 
into the SPPS software format for analysis.  
I based the interpretations of the results on the p value, the value of the R2, the B 
coefficient (the slope coefficient) and the 95% confidence interval (95% CI). The B 
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coefficient represents the change in the dependent variable for a one-unit change in the 
independent variable while all other independent variables are kept constant (Laerd 
statistics, 2015). The B coefficient needs to be statistically significant to be included in 
the equation. R-squared (R2) is the proportion of variance in the dependent variable that is 
accounted for by the independent variables (Laerd statistic, 2015). 
Data Cleaning and Screening 
Missing values. The presence of missing values in a dataset compromises the 
reliability of the study and leads to smaller sample size (Kwak & Kim, 2017). To obtain 
adequate data for analysis, and to avoid selection bias, I exclude all cases that had one or 
more missing values. I applied a listwise deletion technique in SPSS for a complete-case 
analysis.  
Outliers. The presence of outliers in a sample data introduce bias that may lead to 
underestimation or overestimation of statistical results. Both univariate and multivariate 
outliers must be assessed and removed from the data sample to reduce possible bias 
(Kwak & Kim, 2017). I applied winsorization function and the Mahalanobis distance 
function in SPSS to identify, assess and reduce the effect of univariate outliers and 
multivariate outliers. The winsorization consists of replacing the value of the outlier that 
is being tested with an expected value, the largest of the second smallest value in the 
observation (Kwak & Kim, 2017). The Mahalanobis distance function is used to assess 
and reduce the effect of multivariate outliers.  
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In this study, I assessed the following research question and hypotheses and 
conducted a statistical analysis to evaluate the predictor of the health effects of marijuana 
on hepatic function:  
Research question: Is there any significant association between the number of 
joints or pipes of marijuana smoked in a day, the age of initiation, the duration of use and 
each of the serum level of liver function markers including the serum levels of ALT, 
AST, ALB, ALP, TB, TP, and GGT while controlling for the age of participants, their 
gender, the average alcohol use and BMI? 
H01: There is no significant association between the number of joints of marijuana 
smoked in a day, the age of initiation, the duration of use and each of the serum level of 
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and 
GGT while controlling for the age of participants, their gender, the average alcohol use 
and BMI. 
H11: There is significant association between the number of joints of marijuana 
smoked in a day, the age of initiation, the duration of use and each of the serum level of 
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and 
GGT while controlling for the age of participants, their gender, the average alcohol use 
and BMI. 
As stated earlier, I used CSGLM to analyze the data. For validity and inference 
purposes, linear regression requires that the dataset meets some basic assumptions. For 
instance, the outcome variable must be continuous, and one or more of the independent 
variables (s) must be measured either on a continuous or nominal scale. Furthermore, the 
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dependent variables and all independent variables must be mutually exclusive (Osborne, 
2015). Other major assumptions that the dataset must meet to consider using linear 
regression as an appropriate statistical tool to test the hypotheses include the assumption 
of linearity, the assumption of normality, the assumption of no multicollinearity, the 
assumption of homoscedasticity and the assumption of no significant outlier, no high 
leverage points or no highly influential points (Osborne, 2015). 
Major Assumptions of Linear Regression 
Assumption of Linearity 
In linear regression, the independent variables need to be linearly related to the 
dependent variable (Laerd statistic, 2015; Osborne, 2015). However, when in the 
presence of more than one independent variable, the independent variables collectively 
need to be linearly related to the dependent variable (Laerd statistic, 2015) . In this study, 
a scatterplot of the studentized residuals (SRE) against the (unstandardized) predicted 
values was used to evaluate the presence or lack of linearity. The assumption of linearity 
is met if the pattern of a scatterplot allows the presence of a straight line. Otherwise, the 
data is said to fail the assumption of linearity.  
Assumption of Lack of Multicollinearity 
Multicollinearity is basically due to the presence of a high correlation between 
one or more of the independent variables. Multicollinearity makes it difficult to identify 
which independent variable causes the variation in the dependent variable (Leard statistic, 
2015). In this study, two values, the Tolerance (TOL) value and the variance inflation 
factor (VIF) value were used to assess the collinearity. A TOL of less than 0.10 or a VIF 
63 
 
greater than 10 implied the presence of collinearity (University of California, Los 
Angeles [UCLA], n. d). 
Assumption of Normality 
For inferential purposes, the error in prediction also knows as the residual needs 
to be normally distributed (Kutner et al., 2004). The normality was assessed in SPSS 
using Normal Q-Q Plot of the studentized residuals which plot two sets of quantiles again 
each other. The data is normally distributed if the scatterplot forms a straight line (Kutner 
et al., 2004). If the data is extremely skewed, the normality of the distribution may not be 
obtained. However, remediation techniques can be applied to obtain a normal distribution 
of the data (Kutner et al., 2004; Laerd statistic, 2015).  
The Assumption of Homoscedasticity 
Homoscedasticity is a condition required in a linear regression analysis where 
there are equal error variances for all values of the predicted independent variables. 
Homoscedasticity is evaluated in SPSS by plotting the studentized residuals (SRE) 
against the unstandardized predicted values (PRE). Homoscedasticity is present when the 
spread of the residual shows a particular pattern. 
Assumption of Independence of Observations 
One of the major assumptions when using the least square method for regression 
analysis is the lack of autocorrelation in the regression residuals (Kutner et al., 2004). 
The presence of autocorrelation generates regression estimates that may not be effective 
(Kutner et al., 2004). Autocorrelation in the residuals of the regression model has 
traditionally been estimated using the Durbin-Watson (DW) statistic (Bazilevsky, 2018). 
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I used SPSS command through the linear regression analysis to generate the DW values 
in this study. 
Assumption of No Significant Outliers, High Leverage Points, or Highly Influential 
Points 
As described earlier, I used the SPSS univariable outlier identification function to 
assess univariates outliers and I also applied Mahalanobis distance evaluation technique 
to identify and assess the effect of multivariate outliers. The leverage and the influential 
point were measured using Cook's distance. Cook’s distance gives information on the 
residual and the influential point (UCLA, n. d). The lowest value of the Cook’s distance 
is zero, and the higher the Cook’s distance is, the more influential the point is. The cutoff 
point of Cook’s distance is 4/n, where n is the number of observations (UCLA, n. d).  
I conducted a descriptive statistical analysis to better understand of the dataset and 
its different variations. The statistical description included assessing the mean, median, 
mode, variance, the maximum and the minimum values, the skewness and the kurtosis of 
each variable of the study population. I assessed the adequacy of the model and evaluated 
the contribution of each independent variable to the model, and finally interpreted the 
study results. During this study, I set the significance level (p-value) to 0.05 meaning that 
the probability of rejecting a null hypothesis when it was true is 0.05.  
Validity of the Study 
Portino (2018) defined the validity of a research study as to how well the results 
of a study on a sample of a population represent a true finding of that population outside 
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the limit of the study. Portino distinguished two types of validity: internal and external 
validity 
Internal Validity 
Internal validity examines the extent to which a study was designed, conducted, 
analyzed to allow a true result (Andrade, 2018). In brief, the internal validity refers to a 
methodological error in a research study (Portino, 2018). For example, in the current 
study, the internal validity can be threatened by how the participants were selected, how 
the measurement scale was applied, error in recoding the data, consideration in minimum 
sample size, error in data collection, inappropriate analytical plan and statistical tool 
used, and how the results of the study were approached and interpreted. Many research 
techniques were used to improve the internal validity of the current study. These 
techniques included a careful selection of study participants, predetermine minimum 
sample size, appropriate data cleaning, and screening. Furthermore, this study ensured 
that an appropriate statistical tool was used with respect to all required assumptions. 
Analytical plan and results interpretation followed the guidance of several statistical and 
epidemiological manuals authored by Asamoah (2014), Lau (2017), Munnangi and 
Boktor (2018), and Osborne (2015). 
External Validity 
External validity examines if the results of a study apply to a similar population in 
a different setting or if the findings are generalizable to other study contexts (Portini, 
2018; Andrade, 2018). For example, in this study, a good external validity means that the 
findings apply to all 20 to 59 years old marijuana users in the US. Another factor that 
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ensures validity in this research study is the weighting criteria initially applied to the 
NHANES data that I intend to use. Weighting the data produces an estimate 
representative of the general population parameters when the sampling population is 
chosen with unequal probability (NCHS, 2015a). In the context of this study, weighting 
criteria was applied during the analysis to take into consideration the multistage sampling 
technique used during the NHANES survey. To ensure that the study had a good external 
validity, participants were randomly selected from the population, and several statistical 
adjustments were applied for the sample to be representative of the population.  
Ethical Procedure 
Data were accessed from the NHANES website. The NHANES data are public 
data available to be downloaded online. Access to the data requires no permission from 
the NHANES staffs. Data were completely de-identified and anonymous. The NHANES 
protocol was developed and reviewed to comply with requirements for the protection of 
human subjects in research. The policy required ethical treatment of all research subjects 
including vulnerable populations (NCHS, 2015a). The protocol was continuously 
reviewed and amended by the CDC’s Institutional Review Board (IRB). Every 
participant received an inform consent which detailed the survey process and their right 
as survey participants. Information on confidentiality and how their privacy is to be 
protected was also given to the participants in the form of a brochure. Data related to the 
current study were downloaded on an electronic storage device and kept in a safe place. 
Data were uniquely used for this study and will be safely discarded 5 years after the 
study. 
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Summary 
 
The above chapter gives an overview of the different steps in the data analysis 
process from the data collection to the testing of the hypotheses. The rationale of the 
epidemiological design chosen to guide the study, the sampling procedure, the data 
collection procedure, and variables coding were all explained. The chapter also presents 
the different assumptions testing procedures, the data analysis plan, the minimum sample 
size identification procedure, and how the dataset was cleaned to make it appropriate to 
analyze and test the hypotheses. Finally, this chapter presents the scope in which the 
study is valid such as ensuring  that an appropriate statistical tool is used, all required 
assumptions are met, analytical plan and results interpretation followed the guidance of 
statistical and epidemiological theories and that the results of the study apply to a similar 
population in a different setting or the findings are generalizable to other study contexts.  
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Chapter 4: Results  
The purpose of this study was to use a cross-sectional analysis to identify the 
health effects of three potential marijuana use predictors on hepatic function. The health 
effects of the predictor variables associated with marijuana use such as the number of 
joints or pipes of marijuana smoked daily, the age of initiation and the length of time 
marijuana was used were examined. The study was designed to address one research 
question, which was to evaluate if any association exist between the three predictor 
variables and each of the biochemistry profile of the liver, including the serum level of 
ALT, AST, ALB, ALP, TB, TP, and the GGT. This chapter is organized into three 
sections. The first section addresses the data collection and manipulation for analysis, the 
second section evaluates the different assumptions, and the final section presents and 
discusses the study results. 
Data Collection and Manipulation for Analysis 
A combination of four survey cycles of data collected from 2009 to 2016 was 
obtained from NHANES. A total of 40,439 cases were obtained. The dataset included 
data from drug questionnaires and laboratory test results. Variables in the dataset 
included basic demographic variables, such as the age of the participants, their gender, 
and their race. The drug questionnaires included the age at which marijuana was first 
tried, the age at which participants started regularly using marijuana, the time since 
marijuana was last used, and the number of joints or pipes of marijuana used per day. The 
laboratory data included data regarding the biochemistry profile of the liver, such as the 
serum levels of ALT, AST, ALB, ALP, TB, TP, and GGT. The response rate for the 
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NHANES varied from 79.4 and 77.3 for the interview and examination survey, 
respectively, in the 2009-2010 survey cycle to 61.3 and 58.7 in the 2015-2016 survey 
cycle, also respectively. Those in the study dataset only included participants who 
attended both the interview and examination section of the survey and had used 
marijuana during the last 30 days of the survey.  
For analysis purposes and to reduce the risk of biased results due to the presence 
of missing values, all cases with one or more missing values were removed from the 
initial dataset. The removal of the missing cases generated a final sample size of 702 
participants. Figure 3 summarizes all exclusion criteria applied to the initial dataset and 
showed the sample size at each step. 
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Figure 3. Sample size and screening criteria. 
  
71 
 
Data were transformed into different categories as indicated in Chapter 3. The 
number of joints or pipes of marijuana used daily was categorized as 1, 2, 3-5, and 6 or 
more per day. The age of initiation was categorized as teen (under 15 years old), youth 
(15 to 24 years old), and adult (25 to 59 years old). The duration of marijuana use was 
calculated and categorized into five groups: under 10 years, 10 to 19 years, 20 to 29 
years, 30 to 39 years, and 40 and greater than 40 years. Alcohol consumption was 
categorized into light drinkers (less than 2 drinks per day), moderate drinkers (2 to 4 
drinks per day) and heavy drinkers (4 or more drinks per day). BMI was categorized 
following the guidelines recommended by the NHLBI (n.d.) where less than 18.5 was 
defined as underweight, between 18.5 to 24.9 as normal weight, 25 to 29.9 as overweight, 
and 30 or greater as obese. The outcome variables, which comprised the biochemistry 
profile of the liver were continuous variables and were taken as reported. 
Results 
Descriptive Statistics 
The mean age for the participant sample was 37 years with 75% of them being 47 
years old. Approximately, 63% of the participants were male, and 37% were female. 
Non-Hispanic White participants accounted for 67.4% of the sample, while non-Hispanic 
Black represented 14.2%, and, the remaining 18.4% was represented by American 
Mexican, other Hispanic, and multiracial groups. On average, participants tried marijuana 
for the first time at 16 years old, while they started using it regularly at 18 years old. The 
number of joints or pipes used in a day was around two, with 75% of the participants 
smoking three or fewer joints or pipes per day. Among marijuana users, 75% of the 
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participants used marijuana within 13 days of the survey. Approximately, 29.3% of the 
participants used marijuana for less than 10 years of their life, 26.3% used it for 10 to 19 
years, 16.8% used it between 20 to 29 years, 23.8% used it for 30 to 39 years and 3.8% 
used it for more than 40 years, which demonstrated that the length of use was age-
dependent. 
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Table 1 
 
Descriptive Statistics: Categorical Variables 
Variables  Percent (%) Population size 
Gender   
Male 63 5,255,757 
Female 37 3,083,015 
Race   
Mexican American 7.1 588,479 
Other Hispanic 5.1 429,147 
Non-Hispanic White 67.4 5,620,662 
Non-Hispanic Black 14.2 1,188,212 
Other race 6.1 512,272 
Number of joints or pipes smoked/day   
1 per day 42.5 3,540,280 
2 per day 31.2 260,8815 
3-5 per day 20.8 1,735,156 
Six or more per day 5.5 454,521 
Age of initiation   
Teen (<15 yrs.) 26.7 2,228,084 
Youth (15 - 24 yrs.) 64.9 5,413,327 
Adult (25 - 59 yrs.) 8.4 697,361 
Duration of use   
Under 10 yrs. 29.3 2,446,015 
10 to 19 yrs. 26.3 2,190,251 
20 to 29 yrs. 16.8 1,403,711 
30 to 40 yrs. 23.8 1,985,461 
40 yrs. and greater 3.8 313,331 
BMI   
Underweight 1.6 133,126 
Normal weight 31.9 2,656,910 
Overweight 35.9 2,990,771 
Obese 30.7 2,557,965 
Alcohol/day   
Light drinker 39.1 3,257,070 
Moderate drinker 35.1 2,927,236 
Moderate drinker 25.8 2,154,466 
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Table 2 
 
Descriptive Statistics: Continuous Variables 
 Mean Std Error 
95% CI  
Lower Upper 
Population 
size 
Age of participant 37.2 .63 35.9 38.5 8,338,772 
Age of initiation 17.94 .23 17.46 18.41 8,338,772 
ALB 4.36 .02 4.37 4.39 8,338,772 
ALP 63.39 .90 61.53 65.26 8,338,772 
AST 25.07 .55 23.92 26.22 8,338,772 
ALT 25.58 .58 24.39 26.78 8,338,772 
GGT 27.68 1.10 25.40 29.97 8,338,772 
TB .65 .02 .61 .68 8,338,772 
TP 7.05 .030 6.99 7.11 8,338,772 
Avg # alcoholic /day  3.80 .15 3.49 4.12 8,338,772 
BMI 28.13 .22 27.67 28.60 8,338,772 
Duration of use 19.29 .53 18.19 20.38 8,338,772 
 
Preparing for Analysis 
For analysis purposes, I evaluated the dataset for adequate sample size, missing 
data and the normality of the distribution. I also examined the dataset for all required 
assumptions to employ general linear regression analysis.  
Post hoc analysis of sample size. Seven CSGLMs were employed in this study 
corresponding to each of the outcome variables. Each of the CSGLMs yielded a different 
R2 value used to calculate the required sample size. The R2 values obtained from the 
CSGLM analysis ranged from .074 to .287 and achieved a power of 1.00. In short, with a 
sample size of 702 participants and a medium effect size of .15 at alpha .05, a power 
greater than 99% was achieved, which was enough to detect possible associations 
between the variables. 
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Assessing and addressing missing data. The missing data in the NHANES 
survey are data that are completely unavailable due to participants non-response and 
component non-response. The participants non-response occurred both at the interview 
and the medical examination phases of the survey. Not all those who were interviewed 
were selected to participate in the examination phase of the survey, thus creating missing 
data in the examination phase of the survey. The component non-response was related to 
situation where persons who were selected to participant in the medical examination 
phase of the survey did not fully participate in a component of the examination. For 
example, there were individuals who agreed to have their blood drawn but did not get 
their blood pressure taken, thus creating a missing value in the data set. A third situation 
that added to the number of the missing values was when the participants refused to 
answer a particular question or answered ‘unknown’. These values were coded in the 
NHANES as 7, 77, 777 or 9, 99, 999 depending on the number of digits in the variable 
value range. In this study, I also coded these values as missing. 
I used the missing values pattern under the multiple imputations function in SPSS 
to assess the pattern of missing data. Overall, the dataset had eight cases of missing data 
with 99% of complete cases. 
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Figure 4. Summary of missing data. 
 
According to the analytical guideline provided by the NHANES, if 10% or less of 
data for the main outcome variable for a specific component is missing it is acceptable to 
continue analysis without further evaluation or adjustment. In this study, there was less 
than 1% of missing cases, and consequently, a listwise deletion technique was applied to 
the dataset and all cases with one or more missing values were removed. 
Analysis of Assumptions 
Assumption of independence of observations.  
One of the major assumptions when using the least square method for regression 
analysis is the lack of autocorrelation in the regression residuals (Kutner et al., 2004). 
The presence of autocorrelation generates regression estimates that may not be effective. 
Autocorrelation in the residuals of the regression model has traditionally been estimated 
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using the Durbin-Watson (DW) statistic (Bazilevsky, 2018). In this study, I used the 
Durbin-Watson test to evaluate possible autocorrelation between the independent 
variables. The test command is available as an option through the multiple linear 
regression procedure in SPSS. The following table presents the values of DW obtained 
when each of the multiple regression analysis was performed for each outcome variable. 
Table 3 
 
Durbin-Watson Test Results Per Regression Analysis 
 ALT AST ALB ALP TB TP GGT 
Durbin-Watson 1.899 2.070 2.005 1.948 2.022 1.984 1.996 
 
The DW statistic ranged in values from 0 to 4 (Kutner et al., 2004). However, as a 
rule of thumb, a value of 2 indicates that there is no correlation between residuals (Laerd 
Statistics, 2015). In conclusion, after contrasting the values in the above table and the rule 
of thumb, the independence of observations as required for linear regression analysis was 
met.  
Assumption of multicollinearity Evaluation.  
In multiple regression, there must be no correlation between the predictor 
variables (Kutner et al., 2004). Multicollinearity was evaluated through the linear 
regression analysis in SPSS which offers collinearity diagnostic. I obtained two values to 
test for the collinearity, the Tolerance (TOL) and the variance inflation factor (VIF) 
values. The TOL is an indication of the percent of the variance in the predictor that 
cannot be accounted for by the other predictors (UCLA, n. d). The VIF is the reciprocal 
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of the TOL value. A TOL of less than 0.10 (i.e. a VIF greater than 10) implied the 
presence of collinearity (UCLA, n.d.). 
Table 4 
 
TOL &VIF Values Per Regression Analysis 
 
ALT AST ALB ALP TB TP GGT 
Tol VIF TOL VIF TOL VIF TOL VIF TOL VIF TOL VIF TOL VIF 
 Gender .934 1.071 .933 1.072 .934 1.071 .932 1.074 .932 1.074 .932 1.074 .934 1.071
Age in 
years 
.103 9.716 .05617.935 .103 9.716 .05318.961 .05318.961 .05318.961 .103 9.716
# Joints/day .909 1.100 .913 1.096 .909 1.100 .907 1.102 .907 1.102 .907 1.102 .909 1.100
Age of 
initiation 
.521 1.919 .05518.220 .101 9.922 .953 1.049 .953 1.049 .953 1.049 .953 1.049
Duration of 
use 
.101 9.922 .954 1.048 .953 1.049 .924 1.082 .924 1.082 .924 1.082 .924 1.083
BMI .953 1.049 .923 1.083 .924 1.083 .343 2.918 .343 2.918 .343 2.918 .521 1.919
Alcohol/day .924 1.083 .279 3.584 .521 1.919 .05119.493 .05119.493 .05119.493 .101 9.922
 
After conducting an analysis, it appeared that multicollinearity existed in the 
dataset. The control variable age of the participants was correlated to the predictor 
variable “age of initiation” as well as to the variable “alcohol consumed” while the 
regression was performed with respective outcome variable AST, ALP, TB and TP. 
Kutner et al. (2004) advised that the simplest way to remedy the problem of 
multicollinearity is to drop one of the offending variables, although it might affect the 
regression estimates and the R2 values. As a result, the age of participant variable was 
dropped from the analysis where multicollinearities were observed.  
Assumption of normality Evaluation.  
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An initial evaluation of the adequacy of the data for linear regression showed 
histograms of the standardized residuals that appeared to be extremely positively skewed, 
thus generating normality curves that significantly departed from the expected normality. 
According to Laerd Statistic (2015), possible remediation of a variable that is not 
showing normality is to transform the variable. In this study, all outcome variables were 
transformed except for ALB and TP by computing the reciprocal of their data. The 
following figures showed the normality curves before and after the transformations were 
conducted. 
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Normality curve for AST before and after transformation 
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Normality curves for ALT before and after transformation 
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Normality curve for ALB. No transformation needed 
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Normality curves for ALP before and after transformation 
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Normality curves for TB before and after transformation 
 
 
Normality curve for TP. No transformation needed 
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Normality curves for GGT before and after transformation 
Figure 5. Normality curves. 
 
The assumption of normality has then been satisfied after the outcome variables 
were transformed.  
Assumption of homoscedasticity evaluation.  
A major assumption required to apply the least squares regression model is that 
the variance is equal for all values of the predicted dependent variable (Kutner et al., 
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2004). I evaluated the assumption of homoscedasticity by plotting the studentized 
residuals against the unstandardized predicted values. The scatterplots of the different 
multiple regression analyses were shown below. Homoscedasticity is present when the 
spread of the residual shows a particular pattern. In each of the scatterplot below, a 
pattern was not observed. The assumption of homoscedasticity has been met. 
 
Homoscedasticity scatterplot with ALT as the dependent variable 
 
Homoscedasticity scatterplot with AST as the dependent variable 
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Homoscedasticity scatterplot with ALB as the dependent variable 
 
 
Homoscedasticity scatterplot with ALP as the dependent variable 
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Homoscedasticity scatterplot with TB as the dependent variable 
 
 
Homoscedasticity scatterplot with TP as the dependent variable 
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Homoscedasticity scatterplot with GGT as dependent variable 
Figure 6. Homoscedasticity scatterplots. 
Assumption of linearity Evaluation.  
A least squares regression analysis required a linear relationship between the 
dependent and independent variables collectively and between the dependent and each of 
the independent variables (Kutner, et al., 2004; Laerd Statistics, 2015). The scatterplots 
of the studentized residuals against the unstandardized predicted values obtained above 
for the homoscedasticity evaluation were also used to evaluate the collective linearity 
between the predictors and outcome variables. The observation of the scatterplots showed 
that there was a linear relationship between the predictors and the outcome variables.  
The linearity was also evaluated for the relationship between each independent variable 
and the outcome variable. The patterns of scatterplots obtained appeared to be showing 
linearity. As a conclusion, the assumption of linearity has been met.  
Outlier’s Assessment.  
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Outliers are extreme observations. According to Kutner et al. (2004), in the 
regression model, it is difficult to identify outliers by simple graphical means. When in 
the presence of more than one or two predictors variables, a multivariable outlier’s 
analysis may be necessary. In multiple regression analysis, some univariate outliers may 
not be extreme, and, conversely, some multivariable outliers may not be detectable in 
single-variable or two-variable analysis (Kutner et al., 2004). In this study, I used the 
Mahalanobis distance function in SPSS to detect multivariate outliers. I identify three 
outlying cases. To ascertain whether the identified outlier cases were influential, I 
estimated Cook’s distance value for each of them. Cook’s distance combines information 
on residual and Leverage (Kutner et al., 2004). The higher the Cook’s distance, the more 
influential is the outlying point. The conventional cut-off for the Cook’s distance is (k 
+1)/n where k is the number of independent variables in the model, and n is the number 
of observations.  
In the context of this study, the three outliers that were identified had Cook’s distance 
values that were less than .005 (4/702), which was the cut-off for Cook’s distance in the 
study. Although the three cases were identified as outliers, they were not influential in the 
regression analysis. Consequently, these three cases were kept in the dataset for analysis. 
Research Question Analysis 
I analyzed the research question by performing seven different CSGLM analyses, 
with each different liver enzyme as the outcome variable. I based the interpretations of 
the results on the p value, the value of the R2, the B coefficient (the slope coefficient) and 
the 95% confidence interval (95% CI). A parameter was said to contribute to the model, 
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and the null hypothesis rejected if the p value is less than .05 and the 95% CI does not 
include 0. In any other case, a failure to reject the null hypothesis meant that the 
parameter failed to contribute to the model with a p value greater than .05 and a 95% CI 
includes 0. 
During the presentation of the results, the “mean model” was often used. The 
mean model is the model without any predictor variable, it is simply the mean of the 
dependent variable (Laerd Statistics, 2015).  
Part 1 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the number of joints or 
pipes of marijuana use and the serum levels of ALT while controlling for age, gender, 
alcohol use, and BMI? 
To analyze the effect of the three predictor variables on ALT, I performed a  
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the number of joints of marijuana use as predictor variables, 
while the control variables were age, gender, alcohol consumption, and the BMI. ALT 
was used in the regression analysis as the outcome variable. The model revealed a p value 
less than .0005 which satisfied p < .05 with an R2 value of .237, suggesting that the 
presence of all the independent variables produced a model that statistically significantly 
predicted the dependent variable and provided a better fit to the data than the mean 
model. An R2 value of .237 means that the presence of all predictor and control variables 
in the regression model explained 23.7% of the variability observed in ALT. 
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Table 5 
 
Test of Model Effects with ALT as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 16.000 6.000 142.117 .000 
(Intercept) 1.000 21.000 32.055 .000 
Gender 1.000 21.000 60.170 .000 
# of joints/day 3.000 19.000 .424 .738 
Avg # Alcohol 2.000 20.000 4.107 .032 
BMI 3.000 19.000 27.482 .000 
Age of initiation 2.000 20.000 1.075 .360 
Duration of use 4.000 18.000 .536 .711 
Age of participant 1.000 21.000 .158 .695 
a. Model: ALT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + 
Duration of use + Age at screening 
 
Based on the analysis of results presented in the above table, the effect of the age 
of initiation of marijuana on ALT revealed a p value greater than the cut off value of .05, 
F(2, 20) = 1.075, p > .05, and the duration of use also showed a p value greater than .05, 
F(4, 18) = .536, p > .05,. Finally, the effect of the number of joints of marijuana also 
showed a p value greater than .05, F(3, 19) = .424, p > .05. These results suggest that the 
three predictors failed to be statistically significant predictors of the effect of marijuana 
use on ALT. In this case, the null hypothesis, which stated that there is no significant 
association between the age of initiation, the dose of marijuana consumed, and the 
duration of use of marijuana, and ALT failed to be rejected. 
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Table 6 
 
Parameter Estimates with ALT as the Outcome Variable 
Parameter Estimate Std. Error 
95% CI Hypothesis Test  
Lower Upper t df Sig 
(Intercept) .041 .017 .005 .076 2.391 21.000 .026 
Male -.014 .002 -.018 -.010 -7.757 21.000 .000 
Female .000b . . . . . . 
1 joints/day -.003 .003 -.008 .003 -1.093 21.000 .287 
2 joints/day -.001 .002 -.006 .003 -.625 21.000 .539 
3-5 joints/day -.002 .003 -.008 .004 -.590 21.000 .562 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .003 .002 -.001 .007 1.736 21.000 .097 
Moderate drink (2-4 drinks / day) -.002 .003 -.007 .004 -.584 21.000 .566 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) .012 .007 -.002 .026 1.831 21.000 .081 
Normal weight (18.5 – 24.9 kg/ m2) .014 .002 .010 .017 7.479 21.000 .000 
Overweight (25 – 29.9 kg/ m2)  .002 .002 -.002 .006 1.075 21.000 .294 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs old) .004 .004 -.004 .011 .935 21.000 .360 
Initiation as Youth (15 – 24 yrs old) .001 .004 -.008 .010 .303 21.000 .765 
Initiation as Adult (25 – 59 years old) .000b . . . . . . 
< 10 yrs. of use .013 .009 -.006 .032 1.411 21.000 .173 
10 to 19 yrs. of use .011 .008 -.005 .027 1.420 21.000 .170 
20 to 29 of use .007 .006 -.006 .021 1.129 21.000 .271 
30 to 39 yrs. of use .006 .006 -.006 .018 1.062 21.000 .301 
>40 yrs. of use .000b . . . . . . 
Age of participants  6.791E-5 .000 .000 .000 .397 21.000 .695 
a. Model: ALT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration 
of use 
b. Reference category 
 
The analysis of the results presented in the above table revealed that the 
coefficient estimates of the different categories of each of the three predictor variables, 
the age of initiation, the duration of use and the quantity of use failed to be statistically 
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significant. This result was normal considering that the null hypothesis failed to be 
rejected.  
Part 2 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the number of joints or 
pipes of marijuana use and the serum levels of AST while controlling for gender, alcohol 
use and BMI? 
To analyze of the effects of the three predictor variables on AST, I performed a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables, while the 
control variables were, gender, alcohol consumption, and the BMI. AST was used in the 
regression analysis as the outcome variable. In this model, the age of the participants as a 
control variable was dropped due to its correlation with another independent variable in 
the model. The model revealed a significant p < .0005 which satisfied p < .05 with R2 of 
.142, suggesting that the presence of all the independent variables produced a model that 
statistically significantly predicted the dependent variable and provided a better fit to the 
model than the mean model. An R2 value of .142 means that the presence of all predictor 
and control variables in the regression model explained 14.2% of the variability observed 
in AST.  
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Table 7 
 
Test of Model Effects with AST as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 15.000 7.000 34.080 .000 
(Intercept) 1.000 21.000 1079.146 .000 
Gender 1.000 21.000 46.490 .000 
# of joints/day 3.000 19.000 1.189 .341 
Avg # Alcohol 2.000 20.000 2.793 .085 
BMI 3.000 19.000 4.023 .023 
Age of initiation 2.000 20.000 .176 .840 
Duration of use 4.000 18.000 2.781 .058 
a. Model: AST transformed = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of 
initiation + Duration of use  
Based on the analysis of the results presented in the above table, the three 
predictor variables failed to be statistically significant predictors of the effects of 
marijuana use on AST. Consequently, the three predictor variables did not contribute to 
the variation in AST observed above. Here, the statistical significance level of the effects 
of the age of initiation on AST exhibited a value of .840, F(2, 20) = .176, p > .05, while 
the significance level of the dose of marijuana consumed on AST was at .341, F(3 19) = 
1.189, p > .05. Finally, the third predictor variable, the duration of use, showed a 
statistical significance level of .058, F(4, 18) = 2.781, p > .05. The independent effects of 
all three predictor variables showed non-statistically significant p values suggesting that 
the null hypothesis failed to be rejected. 
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Table 8 
 
Parameter Estimates with AST as the Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test  
Lower Upper t df Sig 
(Intercept) .043 .004 .034 .052 10.264 21.000 .000 
Male -.008 .001 -.010 -.006 -6.818 21.000 .000 
Female .000b . . . . . . 
1 joints/day -.002 .002 -.006 .002 -1.056 21.000 .303 
2 joints/day -.001 .002 -.006 .003 -.625 21.000 .539 
3-5 joints/day .000 .002 -.004 .004 -.132 21.000 .896 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .001 .001 -.001 .003 1.101 21.000 .283 
Moderate drink (2-4 drinks / day) -.002 .001 -.003 .000 -1.942 21.000 .066 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) -.002 .004 -.010 .007 -.393 21.000 .698 
Normal weight (18.5 – 24.9 kg/ m2) .002 .001 -.001 .005 1.301 21.000 .207 
Overweight (25 – 29.9 kg/ m2)  -.001 .001 -.004 .002 -.861 21.000 .399 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs. old) .001 .002 -.003 .004 .555 21.000 .585 
Initiation as Youth (15 – 24 yrs. old) .001 .002 -.003 .004 .394 21.000 .697 
Initiation as Adult (25 – 59 yrs. old) .000b . . . . . . 
< 10 yrs. of use .010 .004 .001 .018 2.462 21.000 .023 
10 to 19 yrs. of use .007 .004 -.001 .015 1.865 21.000 .076 
20 to 29 yrs. of use .007 .003 .000 .014 2.228 21.000 .037 
30 to 39 yrs. of use .006 .003 -.001 .013 1.722 21.000 .100 
>40 yrs. of use .000b . . . . . . 
a. Model: AST transformed = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation 
+ Duration of use 
b. Reference category 
The analysis of the above table showed that the coefficient estimates of the 
different categories of the three predictor variables failed to be statistically significant, 
which is normal when the null hypothesis failed to be rejected.  
Part 3 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the number of joints or 
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pipes of marijuana use and the serum levels of ALB while controlling for age, gender, 
alcohol use and BMI? 
To analyze the effects of the three predictor variables on ALB, I performed a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables while the 
control variables were, age, gender, alcohol consumption, and the BMI. ALB was used in 
the regression as the outcome variable. The model revealed a significant p < .0005 which 
satisfied p < .05 with R2 of .194, suggesting that the presence of all the independent 
variables produced a model that statistically significantly predicted the dependent 
variable and provided a better fit for the data than the mean model. An R2 value of .194 
means that the presence of all predictor and control variables in the regression model 
explained 19.4% of the variability observed in ALB. 
Table 9 
 
Test of Model Effects with ALB as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 16.000 6.000 20.489 .001 
(Intercept) 1.000 21.000 388.836 .000 
Gender 1.000 21.000 42.133 .000 
# of joints/day 3.000 19.000 2.250 .116 
Avg # Alcohol 2.000 20.000 1.927 .172 
BMI 3.000 19.000 9.130 .001 
Age of initiation 2.000 20.000 .040 .961 
Duration of use 4.000 18.000 .507 .731 
Age of participants 1.000 21.000 .053 .820 
a. Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + 
Duration of use + age of participants 
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Based on the results of the analysis presented in Table 8, the effect of the age of 
initiation on the ALB revealed a p value greater than .05, F(2, 20) = .040, p > .05 and the 
duration of use also showed a p value than was greater than .05, F(4, 18) = .507, p > .05. 
Finally, the effect of the number of joints of marijuana use also showed a p value that was 
higher than .05, F(3, 19) = 2.250, p > .05. These results suggest that the three predictors 
failed to be statistically significant predictors of the effect of marijuana use on ALB. In 
this case, the null hypothesis which stated that there is no significant association between 
the age of initiation, the dose of marijuana consumed, and the duration of use on ALB 
failed to be rejected. 
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Table 10 
 
Parameter Estimates with ALB as the Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test  
Lower Upper t df Sig 
(Intercept) .245 .017 .210 .281 14.265 21.000 .000 
Male -.010 .002 -.014 -.007 -6.491 21.000 .000 
Female .000b . . . . . . 
1 joints/day .001 .003 -.005 .006 .221 21.000 .827 
2 joints/day .001 .003 -.005 .006 .239 21.000 .813 
3-5 joints/day .004 .002 -.001 .009 1.635 21.000 .117 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .002 .002 -.002 .006 .959 21.000 .348 
Moderate drink (2-4 drinks / day) -.003 .002 -.007 .001 -1.493 21.000 .150 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) -.024 .007 -.039 -.009 -3.381 21.000 .003 
Normal weight (18.5 – 24.9 kg/ m2) -.009 .002 -.013 -.005 -4.739 21.000 .000 
Overweight (25 – 29.9 kg/ m2)  -.008 .002 -.013 -.004 -3.944 21.000 .001 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs. old) .000 .005 -.010 .010 -.088 21.000 .931 
Initiation as Youth (15 – 24 yrs. old) -.001 .004 -.009 .008 -.170 21.000 .867 
Initiation as Adult (25 – 59 years old) .000b . . . . . . 
< 10 yrs. of use -.006 .008 -.023 .011 -.698 21.000 .493 
10 to 19 yrs. of use -.005 .006 -.018 .008 -.790 21.000 .438 
20 to 29 of use -.004 .005 -.014 .006 -.784 21.000 .442 
30 to 39 yrs. of use -.004 .003 -.011 .003 -1.232 21.000 .232 
>40 yrs. of use .000b . . . . . . 
Age of participants 6.347E-5 .000 -.001 .001 .230 21.000 .820 
a. Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of 
initiation + Duration of use + age of participants 
b. Reference category 
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As shown in Table 9, the coefficient estimates of the different categories of the 
three predictor variables failed to be statistically significant with each category showing a 
p value greater than .05.  
Part 4 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the number of joints of 
marijuana use and the serum levels of ALP while controlling for gender, alcohol use and 
BMI? 
To analyze the effect of the three predictor variables on ALP, I performed a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables while the 
control variables were, gender, alcohol consumption, and the BMI. ALP was used in the 
regression analysis as the outcome variable. The model revealed a significant p < .0005 
which satisfied p < .05 with R2 of .074, suggesting that the presence of all the independent 
variables produced a model that statistically significantly predicted the dependent 
variable and that the data was a better fit to the model than the mean model. An R2 value 
of .074 means that the presence of all predictor and control variables into the regression 
model explained 7.4% of the variability observed in ALP. 
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Table 11 
 
Test of Model Effects with ALP as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 15.000 7.000 5.262 .017 
(Intercept) 1.000 21.000 1516.742 .000 
Gender 1.000 21.000 4.161 .054 
# of joints/day 3.000 19.000 1.715 .198 
Avg # Alcohol 2.000 20.000 .236 .792 
BMI 3.000 19.000 3.354 .041 
Age of initiation 2.000 20.000 2.572 .101 
Duration of use 4.000 18.000 4.661 .009 
Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + 
Duration of use  
Based on the results of the analysis presented in of Table 10, the age of initiation 
and the quantity of marijuana use failed to be statistically significant predictors of the 
effect of marijuana use on ALP with respective p values of .101, F(2, 20) = 2.572, p > 
.05, and .198, F( 3, 19) = 1.715, p > 0.05. However, the duration of use showed a 
statistically significant p value level of .009, F(4, 18) = 4.661, p < .05, suggesting that the 
duration of use significantly contributed to the variation in ALP observed above. The 
analysis of the coefficient estimates in the next table shows coefficient estimates values 
for each category of the duration of use that were not statistically significant except for 
the category where participants used marijuana for 10 to 19 years. So, the duration of use 
of marijuana was a statistically significant predictor of the effect of marijuana use on 
ALP. In this case, the null hypothesis partially failed to be rejected for the age of 
initiation of marijuana use and for the quantity of marijuana use, and the alternate 
hypothesis involving the effect of duration of use on ALP was accepted, as the duration 
of use significantly predicted variation on ALP.  
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Table 12 
 
Parameter Estimates with ALP as the Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test  
Lower Upper t df Sig 
(Intercept) .014 .001 .012 .016 13.427 21.000 .000 
Male -.001 .000 -.002 1.811E-5 -2.040 21.000 .054 
Female .000b . . . . . . 
1 joints/day .002 .001 .000 .003 2.382 21.000 .027 
2 joints/day .002 .001 -9.796E-5 .003 1.960 21.000 .063 
3-5 joints/day .001 .001 .000 .003 1.889 21.000 .073 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .000 .001 -.001 .002 .659 21.000 .517 
Moderate drink (2-4 drinks / day) .000 .001 -.001 .002 .571 21.000 .574 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) -.002 .002 -.005 .002 -.958 21.000 .349 
Normal weight (18.5 – 24.9 kg/ m2) .001 .000 .000 .002 1.667 21.000 .110 
Overweight (25 – 29.9 kg/ m2)  .001 .000 .000 .002 2.766 21.000 .012 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs. old) .000 .001 -.002 .001 -.512 21.000 .614 
Initiation as Youth (15 – 24 yrs. old) .001 .001 -.001 .002 1.159 21.000 .259 
Initiation as Adult (25 – 59 yrs. old) .000b . . . . . . 
< 10 yrs. of use .001 .001 -.001 .003 .891 21.000 .383 
10 to 19 yrs. of use .002 .001 .000 .004 2.574 21.000 .018 
20 to 29 of use .000 .001 -.001 .002 .337 21.000 .740 
30 to 39 yrs. of use .000 .001 -.001 .002 .266 21.000 .793 
>40 yrs. of use .000b . . . . . . 
a. Model: ALP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + 
Duration of use + age of participants 
b. Reference category  
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In the above table, except for the estimates of the duration of use of marijuana 
ranging from 10 to 19 years, estimates for other categories of the predictor variables were 
not statistically significant. The estimate of the duration of use for people who used 
marijuana for 10 to 19 years was 0.002, B= .002, p < 0.05, 95%CI [.000 - .004]. This 
result meant that people who used marijuana for 10 to 19 years had a serum ALP value 
that was .002 IU/dl greater those who used marijuana for more than 40 years. Clinically, 
the difference observed was too close to zero, meaning that there was no difference in the 
serum level of ALP between people who used marijuana for 10 to 19 years compared to 
people who used it for more than 40 years. 
Part 5 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the number of joints of 
marijuana use and the serum levels of TB while controlling for gender, alcohol use and 
BMI? 
To analyze the effect of the three predictor variables on TB,  I performed a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables, while the 
control variables were gender, alcohol consumption, and the BMI. TB was used in the 
regression analysis as the outcome variable. The model revealed a significant p < .0005 
which satisfied p < .05 with an R2 value of .106, suggesting that the presence of all the 
independent variables produced a model that statistically significantly predicted the 
dependent variable and is a better fit to the data than the mean model. An R2 value of .106 
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means that the presence of all predictor and control variables in the regression model 
explained 10.6 % of the variability observed in TB.  
Table 13 
 
Test of Model Effects with TB as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 15.000 7.000 20.980 .000 
(Intercept) 1.000 21.000 152.623 .000 
Gender 1.000 21.000 25.738 .000 
# of joints/day 3.000 19.000 4.859 .011 
Avg # Alcohol 2.000 20.000 .374 .692 
BMI 3.000 19.000 3.007 .056 
Age of initiation 2.000 20.000 1.462 .256 
Duration of use 4.000 18.000 1.794 .174 
Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + 
Duration of use 
 
As shown in Table 12, the statistical significance level of the quantity of 
marijuana use was .011, F(3, 19) = 4.859, p < .05, the duration of use was .174, F(4, 18) 
= 1.794, p > .05, and the age of initiation was .256, F(2, 20) = 1.462, p > .05. The p 
values for the quantity of marijuana use was less than the cut-off value of .05. In 
conclusion, the quantity of marijuana use was found to have a statistically significant 
effect on TB. However, the age of initiation and the duration of use failed to have a 
statistical effect on TB. Consequently, the null hypothesis was partially accepted for the 
age of initiation and the duration of use, which means that there is no statistically 
significant association between the age of initiation, the duration of use and TB. For the 
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quantity of marijuana use, the null hypothesis was rejected, meaning that the study found 
a statistically significant association between the quantity of marijuana use and TB.  
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Table 14 
 
Parameter Estimates with TB as the Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test 
Lower Upper t df sig 
(Intercept) 2.912 .394 2.093 3.732 7.388 21.000 .000 
Male -.544 .107 -.767 -.321 -5.073 21.000 .000 
Female .000b . . . . . . 
1 joints/day -.536 .173 -.896 -.175 -3.091 21.000 .006 
2 joints/day -.332 .187 -.722 .057 -1.773 21.000 .091 
3-5 joints/day -.274 .213 -.716 .168 -1.289 21.000 .211 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) -.025 .107 -.247 .198 -.231 21.000 .819 
Moderate drink (2-4 drinks / day) -.104 .117 -.348 .140 -.887 21.000 .385 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) -.577 .368 -1.342 .188 -1.568 21.000 .132 
Normal weight (18.5 – 24.9 kg/ m2) -.310 .128 -.575 -.045 -2.431 21.000 .024 
Overweight (25 – 29.9 kg/ m2)  -.256 .111 -.486 -.026 -2.313 21.000 .031 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs old) .034 .170 -.320 .387 .199 21.000 .844 
Initiation as Youth (15 – 24 yrs old) -.184 .150 -.496 .128 -1.225 21.000 .234 
Initiation as Adult (25 – 59 years old) .000b . . . . . . 
< 10 yrs. of use .122 .218 -.331 .574 .558 21.000 .583 
10 to 19 yrs. of use .260 .141 -.034 .554 1.840 21.000 .080 
20 to 29 of use .048 .148 -.259 .355 .323 21.000 .750 
30 to 39 yrs. of use -.025 .186 -.412 .363 -.133 21.000 .896 
>40 yrs. of use .000b . . . . . . 
a. Model: TB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of 
use  
b. Reference category 
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The results of analysis presented in Table 13, showed that for the variable 
quantity of use, only the category of participants who used 1 joint of marijuana per day 
was statistically significant with a coefficient estimate value of -.536, B= -.536, p < 0.05, 
95%CI [-.896, - .175]. This result meant that people who used 1 joint of marijuana per 
day had a TB level that was .536 mg/dl less than that for those who smoked more than 6 
joints per day, with 95% confident that the difference in TB was between .175 mg/dl and 
.896 mg/dl.  
Part 6 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the quantity of 
marijuana use and the serum levels of TP while controlling for gender, alcohol use and 
BMI? 
To analyze the effect of the three predictor variables on TP, I performed  a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables while the 
control variables were, gender, alcohol consumption, and the BMI. TP was used in the 
regression analysis as the outcome variable. The model revealed a significant p < .0005 
which satisfied p < .05 with an R2 value of .078, suggesting that the presence of all the 
independent variables produced a model that statistically significantly predicted the 
dependent variable better than the mean model and was a better fit for the data. An 
R2value of .077 meant that the presence of all predictor and control variables in the 
regression model explained 7.7% of the variability in TP.  
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Table 15 
 
Test of Model Effects with TP as Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 15.000 7.000 16.975 .000 
(Intercept) 1.000 21.000 23338.468 .000 
Gender 1.000 21.000 3.861 .063 
# of joints/day 3.000 19.000 1.308 .301 
Avg # Alcohol 2.000 20.000 1.276 .301 
BMI 3.000 19.000 1.945 .157 
Age of initiation 2.000 20.000 .050 .952 
Duration of use 4.000 18.000 3.401 .031 
Model: TP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of 
use  
 
 
From the analysis of the results of Table 13, the effect of the age of initiation on 
the TP revealed p value greater than .05, F(2, 20) = .050, p > .05, and that of the quantity 
of use also showed a p value that was greater than 0.05, F(3, 19) = 1.308, p > .05. Finally, 
the effect of the duration of use of marijuana showed a p value of less than .05, F(4, 18) 
= 3.401, p < .05. The preceding results suggest that two of the three predictor variables, 
the age of initiation and the quantity of marijuana use failed to be statistically significant 
predictors of the effect of marijuana use on TP. In this case, the null hypothesis partially 
failed to be rejected for the age of initiation and the quantity of marijuana use while it 
was rejected for the duration of use. 
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Table 16 
 
Parameter Estimates with TP as the Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test 
Lower Upper t df sig 
(Intercept) .150 .004 .141 .159 36.150 21.000 .000 
Male -.002 .001 -.004 9.952E-5 -1.965 21.000 .063 
Female .000b . . . . . . 
1 joints/day -9.854E-5 .002 -.004 .004 -.049 21.000 .962 
2 joints/day -.002 .002 -.005 .002 -1.008 21.000 .325 
3-5 joints/day .000 .002 -.004 .005 .082 21.000 .935 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .001 .001 -.001 .002 1.057 21.000 .303 
Moderate drink (2-4 drinks / day) -.001 .001 -.003 .001 -1.089 21.000 .289 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) -.006 .003 -.013 .000 -1.937 21.000 .066 
Normal weight (18.5 – 24.9 kg/ m2) .000 .001 -.002 .003 .383 21.000 .706 
Overweight (25 – 29.9 kg/ m2)  .000 .001 -.002 .002 -.200 21.000 .843 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs. old) .000 .002 -.004 .003 -.286 21.000 .778 
Initiation as Youth (15 – 24 yrs. old) .000 .002 -.004 .003 -.121 21.000 .905 
Initiation as Adult (25 – 59 years old) .000b . . . . . . 
< 10 yrs. of use -.008 .003 -.013 -.003 -3.058 21.000 .006 
10 to 19 yrs. of use -.005 .002 -.010 -.001 -2.331 21.000 .030 
20 to 29 of use -.005 .002 -.009 .000 -2.192 21.000 .040 
30 to 39 yrs. of use -.005 .003 -.010 .000 -1.915 21.000 .069 
>40 yrs. of use .000b . . . . . . 
a. Model: TP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of 
use  
b. Reference category 
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As shown in Table 16, the coefficient estimates of each category of the predictor 
variables were not statistically significant except for the duration of use, where the 
coefficient estimates of the categories of people who use marijuana for less than 10 years, 
10 to 19 years and 20 to 29 years were all statistically significant with respective 
coefficient estimates of -.008, B = -.008, p < .05, 95%CI[ -.013, -.003], -.005,  B = -.005, 
p < .05, 95%CI[-.010, -.001] and -.005, B = -.005, p < .05, 95%CI[-.009, .000]. These 
result indicate that people who used marijuana for less than 10 years had a TP level that 
was .008 mg/dl less than that of people who used marijuana for more than 40 years, and 
people who used marijuana for 10 to 19 years had a TP level that was .005 mg/dl less 
than that of those who used marijuana for more than 40 years. There was no difference in 
the decreased amount of TP between people who used marijuana for 10 to 19 years and 
20 to 29 years compared to those who used it for more than 40 years. Concisely, the 
difference in TP levels observed for each category of duration of use was too close to 
zero, indicating that the differences were not clinically significant. As a result, there was 
no difference in the serum level of TP for someone who used marijuana for less than 10 
years, 10 to 19 years, and 20 to 29 years compared to those who used the drug for more 
than 40 years.  
Part 7 of the research question. Is there a significant association between the 
duration of marijuana use, the age of initiation of marijuana use, the quantity of 
marijuana use and the serum levels of GGT while controlling for age, gender, alcohol 
use, and BMI? 
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To analyze the effect of the three predictor variables on GGT, I performed a 
complex linear regression analysis in SPSS with the duration of marijuana use, the age of 
initiation of marijuana use, the quantity of marijuana use as predictor variables while the 
control variables were age, gender, alcohol consumption, and the BMI. TP was used in 
the regression analysis as the outcome variable. The model revealed a significance with p 
< .0005 which satisfied p < .05 with an R2 value of .287, suggesting that the presence of 
all the independent variables produced a model that statistically significantly predicted 
the dependent variable and provided a better fit for the data than the mean model. The R2 
value of .287 meant that the presence of all predictors and control variables in the 
regression model explained 28.7 of the variability in GGT. 
Table 17 
 
Test of Model Effects with GGT as the Outcome Variable 
Source df1 df2 Wald F Sig. 
(Corrected Model) 16.000 6.000 49.921 .000 
(Intercept) 1.000 21.000 22.745 .000 
Gender 1.000 21.000 117.066 .000 
# of joints/day 3.000 19.000 .931 .445 
Avg # Alcohol 2.000 20.000 19.181 .000 
BMI 3.000 19.000 10.702 .000 
Age of initiation 2.000 20.000 .409 .670 
Duration of use 4.000 18.000 .989 .438 
Age of participants 1.000 21.000 .586 .452 
Model: GGT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of 
use + Age of participants 
 
As shown in Table 16, the effect of the age of initiation on the GGT revealed a p 
value greater than .05, F(2, 20) = .409, p > .05, and the duration of use also showed a p 
value that was greater than .05, F(4, 18) = .989, p > .05. Finally, the effect of the 
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quantity of use also showed a p value greater than .05, F(3, 19) = .931, p > .05. The 
preceding results suggest that the three predictor variables failed to be statistically 
significant predictors of the effect of marijuana used on GGT. In this case, the null 
hypothesis which stated that there is no significant association between the age of 
initiation, the dose of marijuana consumed, and the duration of use on GGT failed to be 
rejected. 
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Table 18 
 
Parameter Estimates with GGT as Outcome Variable 
Parameter Estimate 
Std. 
Error 
95% CI Hypothesis Test  
Lower Upper t df sig 
(Intercept) .061 .024 .011 .111 2.556 21.000 .018 
Male -.021 .002 -.024 -.017 -10.820 21.000 .000 
Female .000b . . . . . . 
1 joints/day -.006 .007 -.019 .008 -.869 21.000 .395 
2 joints/day -.005 .006 -.017 .007 -.894 21.000 .382 
3-5 joints/day -.003 .006 -.016 .010 -.503 21.000 .620 
6 or more joints/day .000b . . . . . . 
Light drink (< 2 drink / day) .013 .003 .006 .019 4.214 21.000 .000 
Moderate drink (2-4 drinks / day) 1.673E-5 .002 -.005 .005 .007 21.000 .995 
Heavy drink (>= 4 drinks per day) .000b . . . . . . 
Underweight (< 18.5 kg/ m2) .016 .013 -.012 .044 1.186 21.000 .249 
Normal weight (18.5 – 24.9 kg/ m2) .020 .003 .013 .027 5.849 21.000 .000 
Overweight (25 – 29.9 kg/ m2)  .009 .002 .004 .014 3.778 21.000 .001 
Obese (30 kg/ m2 or greater) .000b . . . . . . 
Initiation as Teen (< 15 yrs. old) -.002 .009 -.020 .015 -.283 21.000 .780 
Initiation as Youth (15 – 24 yrs. old) -.003 .007 -.019 .012 -.438 21.000 .666 
Initiation as Adult (25 – 59 years old) .000b . . . . . . 
< 10 yrs. of use .017 .012 -.008 .043 1.413 21.000 .172 
10 to 19 yrs. of use .008 .010 -.013 .029 .785 21.000 .441 
20 to 29 of use .007 .009 -.013 .026 .699 21.000 .492 
30 to 39 yrs. of use .006 .008 -.010 .022 .744 21.000 .465 
>40 yrs. of use .000b . . . . . . 
Age of participants .000 .000 -.001 .000 -.766 21.000 .452 
a. Model: GGT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration 
of use  
b. Reference category 
 
Based on the results presented Table 18, the estimates of each category of the 
three predictor variables were not statistically significant. 
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Summary 
The study was designed to address one research question, which was to evaluate if 
any association exist between the three predictor variables and each of the biochemistry 
profile of the liver, including the serum level of ALT, AST, ALB, ALP, TB, TP, and the 
GGT. After ensuring that the dataset was adequate and met all required assumptions to 
use linear regression to test the hypotheses, the results of the analysis revealed that the 
age of initiation failed to be a significant predictor of the health effect of marijuana on all 
the liver function markers, while the duration of use significantly predicted variations in 
ALP and TP and the quantity of marijuana use was a predictors of the variation in TB 
with an apparent detrimental effect on the serum level of TB level. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
The scope of this study was to identify possible predictors of the health effects of 
marijuana on hepatic function. The primary objective was to assess potential associations 
between the number of joints or pipes of marijuana use, the age of initiation and the 
duration for which marijuana was used with each of the serum levels of liver enzymes 
including the serum level of ALT, AST, ALB, ALP, TB, TP and GGT using a large 
nationally representative sample from the NHANES. Results of the analysis, revealed 
that the age of initiation failed to be a significant predictor of the health effect of 
marijuana on all the liver function markers, while the duration of use significantly 
predicted variations in ALP and TP and the quantity of marijuana use was a predictors of 
the variation in TB. 
Interpretation of the Findings 
Findings related to the health effect of marijuana on the liver are not consistent. 
Studies revealed toxicological and therapeutic health effects on the liver associated with 
marijuana use (Adejumo et al., 2018; Kim et al., 2017; McElrath et al., 2017). The 
findings from prior studies were obtained in many cases from patients with preexisting 
liver conditions where there was a possible lack of assessment of the health effects of the 
predictors on individual liver enzymes. It is important to note that abnormal levels of the 
individual liver enzymes are characteristic of different liver diseases, and thus 
investigating the variation of these enzymes individually is very crucial. Furthermore, 
many scholars, such as Wolkow et al. (2014), have reported that long-term use of 
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marijuana may have detrimental health effects on the liver in a manner similar to the use 
of alcohol and tobacco. 
The Quantity of Marijuana Smoked and the Serum Level of Liver Enzymes 
The findings in this study revealed that the amount of marijuana use is not a 
statistically significant predictor of the health effects of marijuana on the hepatic enzymes 
except for TB. According to this study, people who used 1 joint (or pipe) of marijuana 
per day had a serum TB level that was .536 mg/dl less than that in people who used 6 or 
more joints (or pipes) per day. In other words, heavy marijuana smokers tended to have a 
higher level of serum TB compared to light smokers. This result is consistent with a case-
control study in India that involved 250 male subjects (125 cannabis abusers and 125 in 
the control group), where a significant difference was found in the mean value of TB 
when the two groups were compared. Cannabis abusers exhibited a total bilirubin value 
of 14.78 (SD = 3.10) compared to 11.1 (SD = 3.23) in the control group (Wani et al., 
2017). Similarly, Quraishi et al. (2013) found that the consumption of cannabis increases 
the level of serum bilirubin by 13.72% compared to noncannabis users in a case-control 
study of 30 control subjects and 51 cannabis dependent subjects (mean age of initiation = 
15.31 yrs., SD = 4.7 yrs., duration of cannabis use = 9.53 yrs., SD 8.06 yrs.). In addition, 
Borini et al. (2004) observed that there was no correlation between the amount of 
marijuana use and the serum level of ALT, AST, ALP and GGT, which is also consistent 
with this study’s results. No speculation was made regarding the association between the 
quantity of marijuana use and the serum level of ALB, TB and TP in Borini et al.’s study. 
117 
 
Contrary to the findings in this study, other researchers found that the use of marijuana 
has no detrimental effect on TB (Kotan et al., 2017). 
The quantity of marijuana used is at the core of the discussions regarding the 
predictors of the effects of marijuana on human health. Several studies associated the 
quantity of marijuana use with a lower prevalence of disease and even therapeutic effect 
to the drug (Adejumo et al., 2017; Donghee et al., 2017). The results of the current study 
appeared to contradict these findings. It is apparent that elevated consumption of the drug 
is associated with increased level of TB, which is known to be associated with hemolytic 
jaundice, internal hemorrhage, and acute hemolytic anemia (Bishop et al., 2018). 
Duration of Use and the Serum Levels of Liver Enzymes  
The findings in the current study revealed that the duration of marijuana use is a 
statistically significant predictor of the serum level of ALP and TP in marijuana users but 
failed to be a predictor of the variation in the serum levels of ALT, AST, ALB, TP, and 
GGT. Although there was a significant effect of the duration of use on ALP and TP, there 
was no clinically significant difference in the serum level of ALP and TP when someone 
who had used the drug for less than 10 years was compared to someone who had used it 
for more than 40 years. Several studies have shown that the duration of marijuana use is a 
possible predictor of the health effect of marijuana use of the liver. For example, Quraishi 
et al. (2013) found that using cannabis for more than 9.53 years (SD = 8.06) had 
detrimental health effects on the liver, while Kotan et al. (2017) found that there were no 
health effects when cannabis was used for 30.5 months. It is apparent that the longer 
marijuana is used, the more significant health effects it appears to have. In the current 
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study, the average duration of marijuana use was 19.20 years (SD = 11.68). Still, the 
effect of the duration of use was only significant on ALP and TP levels with no 
difference in the level of ALP and TP among the users was found. The above results 
suggested the need to introduce other epidemiological factors that may improve the 
association between the duration of marijuana use and the level of liver enzymes. It has 
been well known that aging factors, gender, and ethnicity have possible effects on the 
activity of the liver enzymes (Bishop, 2018; Kim et al., 2017; Ruhl & Everhart, 2012; 
Tian et al., 2014). In the present study, the impact of the age of the participants has not 
been adjusted due to its correlation with other independent variables in the regression 
equation. However, the regression equation in this study has been adjusted for gender, for 
ALP, and for TP. The introduction of gender into the regression slightly modified the R2 
value but had no significant effect on the coefficient estimates. Although the results of 
the current study have not been consistent with respect to whether the duration of use has 
a detrimental or therapeutic effect on the liver, it is essential to note that any imbalance 
caused by the consumption of marijuana on TP and ALP is significant. Serum total 
protein, which is mainly synthesized by the liver, is particularly important because it 
serves in the regulation of several physiological functions, maintaining the osmotic 
pressure, transport of various metabolites, and participation in the activity of the immune 
system (Bishop, 2018). As for ALP, variation in the enzyme activity can occur in 
different liver conditions, including liver cirrhosis, chronic hepatitis, and viral hepatitis, 
and in the absence of liver damage such as congestive heart failure, related bone 
disorders and in primary and metastatic cancer (Bishop et al., 2018; Lowe & John, 2018) 
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The Age of Initiation and the Serum Levels of Liver Enzymes  
The findings of the current study revealed that the age of initiation is not a 
statistically significant predictor of the health effect of marijuana on liver enzymes. These 
findings contradicted results from other studies (Quraishi et al., 2013) that indicated the 
age of initiation is a possible predictor of the variations observed in the liver-related 
health parameters. Kotan et al. (2017), for example, found that the age of initiation was a 
significant predictor of the variations in liver enzymes.  
The discrepancy observed in this study compared to other epidemiological studies 
may be evidence of the variations in the age and gender of participants across study 
samples. As much as the effects of age and gender factors were reduced in this study, the 
impact of other potential confounders such as growth factors, nutrition factors, hormone, 
injury factors, and diseases related factors could not be reduced. These factors were all 
known to be contributing factors associated with the variations in levels of liver enzymes.  
Limitations of the Study 
The major strength of this study was that a large, nationally representative sample 
was used. A combination of four survey cycles collected from 2009 to 2015 increased the 
sample size and made it more appropriate for inference purposes. I excluded patients with 
HBV and HCV infection, which have been found to increase liver enzyme levels. The 
participants’ ages were limited to 20 to 59 years old to reduce the effect of aging factors 
known to have a possible effect on observed variations in liver enzymes. Although, the 
inclusion of a control group which in this case should be the non-marijuana users may 
greatly strengthen the ability to draw conclusions from a study (Godby, 2018), I did not 
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consider including control group in this study. Self-reported data are known to be a 
source to bias. In the data sample used for this study, several steps including 
oversampling of the minority population were taken to reduce selection bias. Although 
the study was adjusted for some epidemiological factors such as age and gender, many 
other epidemiological factors, including for example, income level, education level, and 
lifestyle, would have contributed to the variations in liver enzymes and improved the 
relationship between the variables. The study was only adjusted for the effect of BMI. 
However, the effect of several metabolic factors including glucose and cholesterol, which 
had been found to affect the function of the liver, could have been adjusted for a more 
specific relationship between the predictors and outcome variables. Although excluding 
HBV and HCV infected participants from the study may have contributed to reducing the 
selection bias, other disease states, such as liver cirrhosis and liver cancer are known to 
affect the level of liver enzymes (Bishop, 2018). Participants with these diseases have not 
been excluded or the effect of these diseases have not been controlled due to the 
unavailability of pertinent data. Several therapeutic drugs, such as phenobarbital and 
theophylline, have also been found to affect the enzymatic level of the liver (Bishop et 
al., 2018; VanWagner & Green, 2015). Data on these therapeutic drugs were not also 
available to analyze their impact on the level of liver enzymes in the current study.  
It would be interesting to investigate those who use other illicit drugs separately 
from those who use only marijuana to ascertain whether there is a specific relationship 
between the variables. Separating marijuana users from users of other illicit drugs has not 
been investigated in this study, and it is also important to note that several authors have 
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reported on the difficulties in doing so. The statistical methodology applied in this study 
relied on linear regression analysis, which used the least square technique to analyze the 
data. Many other statistical techniques exist, and their application to the current study 
might be more appropriate to enhance the findings to the study. The results of the current 
study were obtained based on hypotheses generated during the study using self-reported 
data and interpretations of the results are limited to the context of this study. However, 
alternative interpretations could not be completely ruled out. 
Recommendations 
This study used a large nationally representative sample to evaluate the health 
effects of three predictor variables, including the quantity of marijuana use, the length of 
time it was used, and the age of initiation, on the level of individual liver enzymes in a 
healthy population. The findings revealed a significant effect of the quantity of marijuana 
smoked on TB, while the duration of use was a statistically significant predictor for levels 
of ALP and TP. The age of initiation failed to predict variations in any of the liver 
enzymes. The study could be improved if marijuana users can be isolated from those 
individuals who use other illicit drugs. It is well known that risk factors associated with 
marijuana abuse include the concurrent use of other illicit drugs (Palamar et al., 2015). In 
addition, illicit use of drugs such as cocaine can lead to several liver abnormalities, 
ranging from mild asymptomatic elevation in liver enzymes to severe liver injury (Pateria 
et al., 2013). Consequently, other illicit drugs are potential confounders in the association 
of marijuana use with the liver, thus reducing the effects of these potential confounders to 
obtain a clear association between marijuana uses and the liver become very important. 
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There is evidence that the pattern and the effects of marijuana use are related to 
race and ethnicity. For example, Pacek et al. (2012) found that marijuana use disorder 
was greatest among African Americans compared to other race/ethnicities. In this study 
sample, 67.4% of participants were non-Hispanic white. As a result, the study did not 
consider a large proportion of the population who use marijuana. More studies with 
different proportions of racial/ethnicities groups as well as studies in the minorities black 
and Hispanic groups are needed to identify if the pattern of marijuana use in relation to 
race and ethnicity is a defining factor in the relationship between marijuana use and liver 
enzymes. The activities of the enzymes in the human body are complex and affected by 
disease stages, lifestyle, nutritional status, and metabolic factors. Thus, they are potential 
confounders in the relationship between marijuana use and the liver. Designing studies 
that can adjust for these factors in a preexisting liver disease population and in a healthy 
population sample is also needed. As observed in this study, the quantity of marijuana use 
has effect on the activity of TB. However, this study is observational by design. There is 
a need for experimental studies to quantify the amount of marijuana that is clinically 
significant to affect the activity of the TB. 
Implications for Social Change 
The results of this study can be used for social change on two significant levels, 
both to improve care management for marijuana users and to improve liver transplant 
denial policy for marijuana users.  
It is not uncommon in the medical diagnostic process to eliminate possible 
illnesses or causes of disease one at a time using clinical information, history and lifestyle 
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of the patient (Committee on Diagnostic Error in Health Care, 2015). Knowing exactly 
the effect of marijuana on the liver enzymes will probably accelerate the process in 
marijuana users and help in accurate diagnosis. 
Despite the inconsistencies in the findings regarding the health effects of 
marijuana on the liver, it remains a schedule I drug in the United States. Furthermore, 
marijuana users are routinely denied liver transplants. Like other studies, the current 
study also revealed that marijuana does not affect all liver enzymes. Accordingly, this 
study adds to the existing literature to help review, or if necessary, to improve the liver 
transplant denial policy for marijuana users.  
Conclusions 
Several studies have evaluated the effects of marijuana use on the liver by 
comparing the prevalence of liver diseases in marijuana users and nonusers or by 
comparing the quantity and the duration of marijuana use in people with preexisting liver 
conditions. In this study, the effects of the drug on the individual liver enzymes was 
evaluated in a healthy population. The study revealed that the length of time marijuana 
was used is a possible predictor of variations in serum levels of ALP and TP although, no 
significant difference has been observed in the level of ALP and TP in relation to whether 
marijuana was used for 10, 20, 30 years compared to those who use it for more than 40 
years. The quantity of marijuana used has also been revealed as a significant predictor of 
variations in the serum level of TB with an apparent detrimental effect on the serum level 
of TB level. Finally, the age of initiation has been found to have no significant effect on 
the variations in the serum levels of liver enzymes.  
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The current study used a nationally representative sample and applied linear 
regression to evaluate hypotheses generated during the study. However, the data on 
marijuana utilization were self-reported, and therefore it may include bias. Several 
epidemiological, physiological and metabolic factors that are known to affect the 
activities of the liver enzymes could have been controlled during analysis to reduce 
potential bias and enhance the relationship between the variables. 
The current study adds to the existing literature to help improve the health of 
marijuana users by first, enhancing the care management of the drug users by 
accelerating the medical diagnostic process, and secondly, by helping to improve liver 
transplant denial policies for marijuana users. 
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